Meet The Professor

Optimizing the Management of Ovarian Cancer

Thursday, August 25, 2022
5:00 PM – 6:00 PM ET

Faculty

Richard T Penson, MD, MRCP

Moderator

Neil Love, MD

RTP
RESEARCH
TO PRACTICE

Commercial Support

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Merck, and Mersana Therapeutics Inc.

Dr Love — Disclosures

Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

RTP
RESEARCH
TO PRACTICE

Research To Practice CME Planning Committee Members, Staff and Reviewers

Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Dr Penson — Disclosures

Advisory Committee	AstraZeneca Pharmaceuticals LP, Eisai Inc, GlaxoSmithKline, ImmunoGen Inc, Merck, Mersana Therapeutics Inc, Novocure Inc, Roche Laboratories Inc, Sutro Biopharma, VBL Therapeutics
Contracted Research	Array BioPharma Inc, a subsidiary of Pfizer Inc, AstraZeneca Pharmaceuticals LP, Eisai Inc, Genentech, a member of the Roche Group, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Tesaro, A GSK Company, VBL Therapeutics
Data and Safety Monitoring Board/Committee	AstraZeneca Pharmaceuticals LP, Roche Laboratories Inc
Royalties	BMJ Publishing Group Ltd, Elsevier, Wiley-Blackwell, Wolters Kluwer Health

We Encourage Clinicians in Practice to Submit Questions



Feel free to submit questions now before the program begins and throughout the program.

RTP RESEARCH TO PRACTICE

Familiarizing Yourself with the Zoom Interface

Expand chat submission box



Drag the white line above the submission box up to create more space for your message.

RTP RESEARCH TO PRACTICE

Familiarizing Yourself with the Zoom Interface

Increase chat font size



Press Command (for Mac) or Control (for PC) and the + symbol.
You may do this as many times as you need for readability.

Clinicians in the Audience, Please Complete the Pre- and Postmeeting Surveys



RTP RESEARCH TO PRACTICE

ONCOLOGY TODAY

WITH DR NEIL LOVE

Updates on Ovarian Cancer from SGO 2022

DR DAVID O'MALLEY

THE OHIO STATE UNIVERSITY AND
THE JAMES CANCER CENTER

Listen on Apple Podcasts

Spotify

Listen on Google Podcasts

Meet The Professor

Current and Future Management of Non-Small Cell Lung Cancer with an EGFR Mutation

Wednesday, August 31, 2022
5:00 PM – 6:00 PM ET

Faculty

Lecia V Sequist, MD, MPH

Moderator

Neil Love, MD

RTP
RESEARCH
TO PRACTICE

Meet The Professor

Optimizing the Management of HER2-Positive Breast Cancer

Thursday, September 1, 2022
5:00 PM – 6:00 PM ET

Faculty

Mark D Pegram, MD

Moderator

Neil Love, MD

RTP
RESEARCH
TO PRACTICE

Exploring Current Considerations and Promising Investigational Approaches for Patients with Myelodysplastic Syndromes

A CME/MOC-Accredited Virtual Event

Thursday, September 8, 2022

5:00 PM – 6:00 PM ET

Faculty

Guillermo Garcia-Manero, MD
Gail J Roboz, MD
David Sallman, MD

Moderator

Neil Love, MD

RTP
RESEARCH TO PRACTICE

Challenging Cases from the Community: Investigators Provide Perspectives on the Optimal Management of Diffuse Large B-Cell Lymphoma

A CME/MOC-Accredited Virtual Event

Tuesday, September 13, 2022
5:00 PM – 6:00 PM ET

Faculty

Sonali M Smith, MD
Additional faculty to be announced

Moderator

Neil Love, MD

RTP RESEARCH TO PRACTICE

Current Paradigm and Future Directions for Immunotherapy in the Treatment of Metastatic Non-Small Cell Lung Cancer

A CME/MOC-Accredited Virtual Event

Tuesday, September 27, 2022
5:00 PM – 6:00 PM ET

Faculty

Faculty to be announced

Moderator

Neil Love, MD

RTP
RESEARCH
TO PRACTICE

Thank you for joining us!

CME and MOC credit information will be emailed to each participant within 5 business days.

RTP
RESEARCH
TO PRACTICE

Meet The Professor
Optimizing the Management of Ovarian Cancer

Richard T Penson, MD, MRCP
Associate Professor of Medicine
Harvard Medical School
Clinical Director, Medical Gynecologic Oncology
Massachusetts General Hospital
Boston, Massachusetts

Meet The Professor Program Participating Faculty

Ramez N Eskander, MD
Associate Clinical Professor of Obstetrics, Gynecology and Reproductive Sciences
UC San Diego Health
La Jolla, California

Stephanie Lheureux, MD, PhD
Drug Development Program - Gynecology
Division of Medical Oncology and Hematology
Gynecology Site Lead
Co-Director of the Beyond Chemotherapy Program
Princess Margaret Cancer Centre
Associate Professor
University of Toronto
Toronto, Ontario, Canada

Prof Jonathan A Ledermann
Professor of Medical Oncology
UCL Cancer Institute
London, United Kingdom

Ursula Matulonis, MD
Chief, Division of Gynecologic Oncology
Brock-Wilson Family Chair
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

RTP
RESEARCH TO PRACTICE

Meet The Professor Program Participating Faculty

Richard T Penson, MD, MRCP
Associate Professor of Medicine
Harvard Medical School
Clinical Director, Medical Gynecologic Oncology
Massachusetts General Hospital
Boston, Massachusetts

MODERATOR
Neil Love, MD
Research To Practice

Shannon N Westin, MD, MPH
Associate Professor
Director, Early Drug Development
Department of Gynecologic Oncology and
Reproductive Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas

RTP
RESEARCH
TO PRACTICE

We Encourage Clinicians in Practice to Submit Questions



Feel free to submit questions now before the program begins and throughout the program.

RTP RESEARCH TO PRACTICE

Clinicians in the Audience, Please Complete the Pre- and Postmeeting Surveys



RTP RESEARCH TO PRACTICE

ONCOLOGY TODAY

WITH DR NEIL LOVE

Updates on Ovarian Cancer from SGO 2022

DR DAVID O'MALLEY

THE OHIO STATE UNIVERSITY AND
THE JAMES CANCER CENTER

Listen on Apple Podcasts

Spotify

Listen on Google Podcasts

Meet The Professor

Current and Future Management of Non-Small Cell Lung Cancer with an EGFR Mutation

Wednesday, August 31, 2022
5:00 PM – 6:00 PM ET

Faculty

Lecia V Sequist, MD, MPH

Moderator

Neil Love, MD

RTP
RESEARCH
TO PRACTICE

Meet The Professor

Optimizing the Management of HER2-Positive Breast Cancer

Thursday, September 1, 2022
5:00 PM – 6:00 PM ET

Faculty

Mark D Pegram, MD

Moderator

Neil Love, MD

RTP
RESEARCH
TO PRACTICE

Exploring Current Considerations and Promising Investigational Approaches for Patients with Myelodysplastic Syndromes

A CME/MOC-Accredited Virtual Event

Thursday, September 8, 2022

5:00 PM – 6:00 PM ET

Faculty

Guillermo Garcia-Manero, MD
Gail J Roboz, MD
David Sallman, MD

Moderator

Neil Love, MD

RTP
RESEARCH TO PRACTICE

Challenging Cases from the Community: Investigators Provide Perspectives on the Optimal Management of Diffuse Large B-Cell Lymphoma

A CME/MOC-Accredited Virtual Event

Tuesday, September 13, 2022
5:00 PM – 6:00 PM ET

Faculty

Sonali M Smith, MD
Additional faculty to be announced

Moderator

Neil Love, MD

RTP RESEARCH TO PRACTICE

Current Paradigm and Future Directions for Immunotherapy in the Treatment of Metastatic Non-Small Cell Lung Cancer

A CME/MOC-Accredited Virtual Event

Tuesday, September 27, 2022
5:00 PM – 6:00 PM ET

Faculty

Faculty to be announced

Moderator

Neil Love, MD

RTP
RESEARCH
TO PRACTICE

Meet The Professor
Optimizing the Management of Ovarian Cancer

Richard T Penson, MD, MRCP
Associate Professor of Medicine
Harvard Medical School
Clinical Director, Medical Gynecologic Oncology
Massachusetts General Hospital
Boston, Massachusetts

Commercial Support

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Merck, and Mersana Therapeutics Inc.

Research To Practice CME Planning Committee Members, Staff and Reviewers

Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Dr Penson — Disclosures

Advisory Committee	AstraZeneca Pharmaceuticals LP, Eisai Inc, GlaxoSmithKline, ImmunoGen Inc, Merck, Mersana Therapeutics Inc, Novocure Inc, Roche Laboratories Inc, Sutro Biopharma, VBL Therapeutics
Contracted Research	Array BioPharma Inc, a subsidiary of Pfizer Inc, AstraZeneca Pharmaceuticals LP, Eisai Inc, Genentech, a member of the Roche Group, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Tesaro, A GSK Company, VBL Therapeutics
Data and Safety Monitoring Board/Committee	AstraZeneca Pharmaceuticals LP, Roche Laboratories Inc
Royalties	BMJ Publishing Group Ltd, Elsevier, Wiley-Blackwell, Wolters Kluwer Health

Bruce Bank, MD
Northwest Oncology and Hematology
Rolling Meadows, Illinois

Karim ElSahwi, MD
Hackensack Meridian Health
Neptune City, New Jersey

Gigi Chen, MD
John Muir Health
Pleasant Hill, California

Dana M Chase, MD
Arizona Center for Cancer Care
Phoenix, Arizona

Paul DiSilvestro, MD
Women and Infants Hospital of Rhode Island/Alpert School of Medicine at Brown
Providence, Rhode Island

Priya Rudolph, MD
Georgia Cancer Specialists
Northside Hospital Cancer Institute
Athens, Georgia

RTP
RESEARCH TO PRACTICE

Meet The Professor with Dr Penson

Introduction: Journal Club with Dr Penson – Part 1

MODULE 1: Case Presentations

MODULE 2: Faculty Survey

MODULE 3: Journal Club with Dr Penson – Part 2

MODULE 4: Appendix of Key Publications

RTP
RESEARCH
TO PRACTICE

Meet The Professor with Dr Penson

Introduction: Journal Club with Dr Penson – Part 1

MODULE 1: Case Presentations

MODULE 2: Faculty Survey

MODULE 3: Journal Club with Dr Penson – Part 2

MODULE 4: Appendix of Key Publications

RTP
RESEARCH
TO PRACTICE

Select Antibody-Drug Conjugates in Oncology

Multiple Myeloma: Belantamab mafodotin

Hodgkin Lymphoma: Brentuximab vedotin

Diffuse Large B-Cell Lymphoma: Polatuzumab vedotin, loncastuximab tesirine

Breast Cancer: Sacituzumab govitecan, trastuzumab deruxtecan (T-DXd), trastuzumab emtansine (T-DM1)

Bladder Cancer: Enfortumab vedotin, sacituzumab govitecan, disitamab vedotin

Lung Cancer: T-DXd, patritumab deruxtecan, datopotamab deruxtecan

Cervical Cancer: Tisotumab vedotin

Ovarian Cancer: Mirvetuximab soravtansine, upifitamab rilsodotin

Mirvetuximab Soravtansine: Mechanism of Action



(1) Mirvetuximab soravtansine binds with high affinity to FRα expressed on the tumor cell surface

(2) The antibody-drug conjugate (ADC)/receptor complex becomes internalized via antigen-mediated endocytosis

(3) Lysosomal processing releases active DM4 catabolites from the ADC molecule

(4) These maytansinoid derivatives inhibit tubulin polymerization and microtubule assembly

(5) The potent antimitotic effects result in cell-cycle arrest and apoptosis

(6) Active metabolites can also diffuse into neighboring cells and induce further cell death — in other words, bystander killing

Moore K et al. *Future Oncol* 2018:14(2);123-36.

RTP RESEARCH TO PRACTICE

Mirvetuximab Soravtansine (MIRV) in Patients with Platinum-Resistant Ovarian Cancer with High Folate Receptor Alpha (FRα) Expression: Characterization of Antitumor Activity in the SORAYA Study

Matulonis UA et al.

ASCO 2022;Abstract 5512.

MIRASOL Phase III Study Schema

MIRASOL

Enrollment and Key Eligibility

- Platinum-resistant disease (PFI ≤ 6 mo)
  - 1° platinum refractory disease excluded (primary PFI < 3 mo)
- Prior bevacizumab and PARPi allowed
- 1-3 prior lines of therapy
- Patients with BRCA mutations allowed
- FRα-high by PS2+ scoring (≥75% PS2+)

Statistical Assumptions

- 430 patients/ 330 events for PFS by INV
- α=0.05 (two-sided)
- Power=90%; HR=0.7; control arm mPFS 3.5 mo

Mirvetuximab Soravtansine
6 mg/kg AIBW (calculated using adjusted ideal body weight) intravenously once every 3 weeks

1:1 Randomization
STRATIFICATION FACTORS
Investigator's Choice (IC) Chemotherapy
(Paclitaxel, PLD, Topotecan)
Prior Therapies
(1 vs 2 vs 3)

Investigator's Choice (IC) Chemotherapy
Paclitaxel, PLD,† or Topotecan
Paclitaxel: 80 mg/m2 weekly; PLD: 40 mg/m² every 4 weeks;
Topotecan: 4 mg/m² on days 1, 8, and 15 every four weeks;
or 1.25 mg/m² on days 1-5 every 3 weeks

Moore KN et al. SGO 2022;Abstract 297.

2021 ASCO ANNUAL MEETING

Abstract 5550

PHASE 1 DOSE-ESCALATION STUDY OF STRO-002, AN ANTI–FOLATE-RECEPTOR ALPHA ANTIBODY DRUG CONJUGATE, IN PATIENTS WITH ADVANCED, PROGRESSIVE, PLATINUM-RESISTANT/-REFRACTORY EPITHELIAL OVARIAN CANCER

R. Wendel Naumann,[1] Fadi S. Braiteh,[2] Lainie P. Martin,[3] Erika Hamilton,[4] John P. Diaz,[5] Sami Diab,[6] Russell J. Schilder,[7] John W. Moroney,[8] Denise Uyar,[9] David M. O'Malley,[10] Richard T. Penson,[11] Clifford DiLea,[12] Michael Palumbo,[13] Venita DeAlmeida,[13] Shannon Matheny,[13] Lin Lu,[13] Craig J. Berman,[13] Arturo Molina[13]

[1]Levine Cancer Institute, Atrium Health, Charlotte, NC; [2]Comprehensive Cancer Centers of Nevada, Las Vegas, NV; [3]University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA; [4]Sarah Cannon Research Institute, Tennessee Oncology PLLC, Nashville, TN; [5]Miami Cancer Institute at Baptist Health, Miami, FL; [6]Rocky Mountain Cancer Center, Aurora, CO; [7]Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; [8]University of Chicago, Chicago, IL; [9]Medical College of Wisconsin, Milwaukee, WI; [10]Ohio State University, Wexner Medical Center, Columbus, OH; [11]Massachusetts General Hospital, Boston, MA; [12]Aclairo Pharmaceutical Development Group, Vienna, VA; [13]Sutro Biopharma, Inc., South San Francisco, CA

R. Wendel Naumann

Levine Cancer Institute, Atrium Health, Charlotte, NC

June 4–8, 2021

JC JOURNAL CLUB RTP RESEARCH TO PRACTICE

Baseline Characteristics and TEAEs

Baseline characteristics

Baseline characteristic	All patients (N = 39)
Age, median (range), years	61 (48–79)
Time since diagnosis, median (range), years	3.9 (0.7–17.0)
No. of prior lines of therapy, median (range)	6 (1–11)
Previous therapies, n (%)	
Platinum	39 (100)
≥ 3 prior platinum regimens	18 (46)
Taxanes	38 (97)
Bevacizumab	32 (82)
Poly (ADP-ribose) polymerase inhibitors	23 (59)
Checkpoint inhibitors	8 (21)
Experimental therapy	14 (36)

- The novel FRα-targeting ADC STRO-002 exhibited a generally well-tolerated safety profile in heavily pretreated patients with progressive EOC

Most frequent TEAEs > 25% by grade[a]

All safety-evaluable patients, n (%)	Grade 1	Grade 2	Grade 3	Grade 4	Overall (N = 39)
Fatigue	7 (18)	19 (49)	4 (10)	0	30 (77)
Nausea	15 (39)	11 (28)	0	0	26 (67)
Constipation	12 (31)	13 (33)	0	0	25 (64)
Neutropenia[b]	0	0	8 (21)	17 (44)	25 (64)
Decreased appetite	10 (26)	10 (26)	0	0	20 (51)
Arthralgia	7 (18)	7 (18)	5 (13)	0	19 (49)
Neuropathy[c]	3 (8)	13 (33)	3 (8)	0	19 (49)
Abdominal pain	7 (18)	6 (15)	3 (8)	0	16 (41)
Vomiting	8 (21)	7 (18)	0	0	15 (39)
AST increased	10 (26)	3 (8)	2 (5)	0	15 (39)
Diarrhea	8 (21)	3 (8)	1 (3)	0	12 (31)
Dizziness	9 (23)	3 (8)	0	0	12 (31)
Dry eye	4 (10)	8 (21)	0	0	12 (31)
Anemia	3 (8)	6 (15)	2 (5)	0	11 (28)
Pyrexia	8 (21)	3 (8)	0	0	11 (28)
Headache	7 (18)	3 (8)	0	0	10 (26)
Insomnia	6 (15)	4 (10)	0	0	10 (26)

[a]Two grade 5 events were reported as unrelated to study drug by investigator assessment, 1 death not otherwise specified and 1 acute gastrointestinal bleed. [b]Neutropenia included the following preferred terms: neutropenia, febrile neutropenia, and neutrophil count decreased. [c]Neuropathy included the following preferred terms: neuropathy peripheral and peripheral sensory neuropathy.
ADP, adenosine diphosphate; AST, aspartate aminotransferase.

TEAE = treatment-emergent adverse event

Naumann RW et al. ASCO 2021;Abstract 5550.

Efficacy

- STRO-002 exhibited clinical efficacy as demonstrated by objective responses: 1 CR, 4 PR, and 5 PRu

Maximum change[a] in tumor target lesions in RECIST-evaluable patients treated with STRO-002 ≥ 2.9 mg/kg Q3W (N = 31)



Objective response per RECIST v1.1	RECIST-evaluable population (N = 31)
Responders	10
CR[b]	1
PR	9
Confirmed	4
Unconfirmed	5
SD	18
PD	3

[a]Maximum percentage change from baseline in sum of longest diameter in evaluable patients treated with STRO-002 at ≥ 2.9 mg/kg Q3W (N = 31). [b]CR in patient treated at 2.9 mg/kg with resolution of peritoneal disease. CR, complete response; PD, progressive disease; PR, partial response; PRu, unconfirmed partial response; SD, stable disease. Data cutoff was April 23, 2021.

Naumann RW et al. ASCO 2021;Abstract 5550.

Disease Control Rate and Progression-Free Survival

- Disease control rate was 61% and 55% at ≥ 16 and 24 weeks, respectively
- Median PFS was 7.2 months (95% CI, 4.5–10.8)

Treatment duration[a] and response in RECIST-evaluable patients treated with STRO-002 ≥ 2.9 mg/kg Q3W (N = 31)



Disease control rate (DCR, weeks)	RECIST-evaluable population, n (%)
≥ 52 weeks	5 (16)
≥ 24 weeks	17 (55)
≥ 16 weeks	19 (61)

Most patients on treatment **beyond 12 weeks** were treated at the **2.9 to 5.2 mg/kg dose levels**

Naumann RW et al. ASCO 2021;Abstract 5550.

Updated Results From the Phase 1b Expansion Study of Upifitamab Rilsodotin (UpRi; XMT-1536), a NaPi2b-directed Dolaflexin Antibody Drug Conjugate (ADC) in Ovarian Cancer

Richardson, Debra L[1]; Hamilton, Erika P[2]; Barve, Minal[3]; Anderson, Charles K[4]; Taylor, Sara K[5]; Lakhani, Nehal[6]; Buscema, Joseph[7]; Tolcher, Anthony W[8]; Zarwan, Corrine[9]; Werner, Theresa L[10]; Hays, John L[11]; Richards, Paul[12]; Arend, Rebecca[13]; Edenfield, Jeffery[14]; Putiri, Emily[15]; Bernardo, Patricia[15]; Burger, Robert A[15]; Matulonis, Ursula A[16]

[1]Stephenson Cancer Center, University of Oklahoma Health Sciences Center and the Sarah Cannon Research Institute, Oklahoma City, OK; [2]Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; [3]Mary Crowley Cancer Research, Dallas, TX; [4]Willamette Valley Cancer Institute and Research Center, Eugene, OR; [5]BC Cancer - Kelowna, Kelowna BC, Canada; [6]START Midwest, Grand Rapids, MI; [7]Arizona Oncology, Tucson, AZ; [8]NEXT Oncology, San Antonio, TX; [9]Lahey Clinic, Burlington, MA; [10]Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; [11]Arthur James Cancer Hospital, Ohio State University, Columbus, OH; [12]US Oncology, Oncology and Hematology Assoc. of Southwest VA, Salem, VA; [13]University of Alabama at Birmingham, Birmingham, AL; [14]Prisma Health Cancer Institute, Greenville, SC; [15]Mersana Therapeutics, Inc, Cambridge, MA; [16]Dana-Farber Cancer Institute, Boston, MA

Abstract 76

ANNUAL MEETING ON WOMENS' CANCER®
BUILDING BRIDGES // BREAKING BARRIERS
SGO // PHOENIX, ARIZONA // MARCH 18 - 21, 2022

SGO 2022;Abstract 76.

Society of Gynecologic Oncology

Upifitamab Rilsodotin (UpRi): First-in-Class ADC Targeting NaPi2b



UpRi

Antibody: Humanized monoclonal anti-NaPi2b[1]

Linker: Polymer scaffold; cleavable ester linker[2]

Payload: AF-HPA (DolaLock-controlled bystander effect)[1]

Drug-to-Antibody Ratio: ~10



Upon ADC internalization into tumor cells and efficient release of payload, AF-HPA payload is metabolized to AF that remains highly potent but loses the ability to cross the cell membrane, locking it in the tumor, controlling the bystander effect, and consequently limiting impact on adjacent healthy cells[2,3]

NaPi2b Is a Sodium-Dependent Phosphate Transporter Broadly Expressed in Ovarian Cancer With Limited Expression in Healthy Tissues[4]

- NaPi2b expressed by tumor cells in two-thirds of patients with high-grade serous ovarian cancer[2]
- NaPi2b is a lineage antigen (not an oncogene)[1]



NaPi2b IHC assay in development *– an optimal diagnostic assay would be robust, predictive, reproducible, easily able to distinguish a wide range of expression using* ***TPS scoring method***[2]



Richardson DL et al. SGO 2022;Abstract 76.

RTP RESEARCH TO PRACTICE

Best Response by UpRi Dose Group

Similar Tumor Reduction in Both Dose Groups: Two-thirds of Patients Had Reductions in Target Tumor Lesions by RECIST 1.1



Richardson DL et al. SGO 2022;Abstract 76.

Confirmed ORR by UpRiDose Group and NaPi2b Level and Duration of Response (DoR)

		All Dose Levels	Dose Group 36	Dose Group 43
NaPi2b-High (TPS ≥75)	N	38	16	22
	ORR, n (%)	**13 (34)**	**7 (44)**	**6 (27)**
	CR, n (%)	2 (5)	2 (13)	0
	PR, n (%)	11 (29)	5 (31)	6 (27)
	DCR, n (%)	33 (87)	12 (75)	21 (95)
All NaPi2b Levels	N	75	25	48
	ORR, n (%)	**17 (23)**	**9 (36)**	**8 (17)**
	CR, n (%)	2 (3)	2 (8)	0
	PR, n (%)	15 (20)	7 (28)	8 (17)
	DCR, n (%)	54 (72)	18 (72)	35 (73)

- **Median DoR in patients (all dose levels) with NaPi2b-high ovarian cancer (n=13): 5 months**
- No obvious difference in median DoR observed between Dose Groups 36 and 43

Richardson DL et al. SGO 2022;Abstract 76.

Time on UpRi Study in Evaluable Patients



Richardson DL et al. SGO 2022;Abstract 76.

TRAEs by UpRi Dose Group

Dose Group 36 Had a More Favorable Safety Profile Compared to Dose Group 43



- No severe ocular toxicity, neutropenia, or peripheral neuropathy in either dose group
- 4 (14%) patients had treatment-related SAEs in Dose Group 36 vs 18 (27%) in Dose Group 43
- Lower frequencies and lower grade pneumonitis occurred in Dose Group 36 (with no Grade 3+) vs Dose Group 43[a]

Richardson DL et al. SGO 2022;Abstract 76.

RTP RESEARCH TO PRACTICE

Ongoing UPLIFT (ENGOT-OV67/GOG-3048) Study Schema



Richardson DL et al. SGO 2022;Abstract 76.

Ongoing UP-NEXT Phase III (ENGOT-OV71-NSGO-CTU/GOG-3049) Study Schema



Richardson DL et al. SGO 2022;Abstract 76.

Meet The Professor with Dr Penson

MODULE 1: Case Presentations

- Dr Chen: 76-year-old woman with Stage IIIB BRCA WT HGSOC, s/p neo/adjuvant carboplatin/paclitaxel, and severe thrombocytopenia on maintenance niraparib
- Dr Chase: 38-year-old woman with Stage IIC BRCA WT HGSOC s/p surgery and carboplatin/paclitaxel – LOH-negative
- Dr DiSilvestro: 62-year-old woman with Stage IIIC HGSOC and a gBRCA1 mutation receives IV/IP paclitaxel/cisplatin
- Dr ElSahwi: 60-year-old woman with BRCA WT, HRD-negative peritoneal cancer s/p neo/adjuvant carboplatin/paclitaxel presents with altered mental status and a cerebellar metastasis
- Dr Chase: 72-year-old woman with multiregimen-recurrent endometrioid ovarian adenocarcinoma with a gPALB2 mutation develops breast cancer during maintenance niraparib
- Dr Bank: 76-year-old woman with Stage IV ovarian cancer goes for debulking surgery after carboplatin/paclitaxel and maintenance niraparib
- Dr Rudolph: 69-year-old woman with Stage IV BRCA WT, HRD-negative HGSOC develops anemia on maintenance olaparib/bevacizumab
- Dr DiSilvestro: 57-year-old woman (s/p donor nephrectomy) with Stage IIIA HGSOC, gBRCA1 mutant
- Dr ElSahwi: 59-year-old woman with primary peritoneal cancer, gBRCA1 mutant, develops a small pelvic recurrence after neo/adjuvant chemotherapy and surgery
- Dr Chen: 53-year-old woman with locally recurrent ovarian cancer (BRCA WT) develops lymphedema on maintenance bevacizumab/niraparib

RTP RESEARCH TO PRACTICE

Case Presentation: 76-year-old woman with Stage IIIB BRCA WT HGSOC, s/p neo/adjuvant carboplatin/paclitaxel, and severe thrombocytopenia on maintenance niraparib

Dr Gigi Chen (Pleasant Hill, California)

RTP
RESEARCH
TO PRACTICE

Ovarian cancer 1L PARPi maintenance trials: design and populations

Trial	PARP inhibitor	Duration	BRCA status	R0 at PDS allowed	% PDS	CR/PR to platinum
SOLO1[1,2]	Olaparib	2 years	*BRCA*mt only	Yes	62.9	Yes
PRIMA[3]	Niraparib	3 years	All comers	No if Stage III	33	Yes
PRIME[4]	Niraparib	3 years	All comers	Yes	53.1	Yes
PAOLA1[5]	Olaparib (w/bevacizumab)	2 years	All comers	Yes	50.7	Yes
VELIA[6]	Veliparib (w/chemo)	36 total cycles	All comers	Yes	67.5	No (tx starts with chemo)
ATHENA-MONO[7]	Rucaparib	2 years	All comers	Yes	48.9	Yes

[1]Moore et al., *N Engl J Med* 2018; [2]Banerjee et al., 2020 ESMO Congress; [3]Gonzalez-Martin et al., *N Engl J Med* 2019; [4]Li et al., 2022 SGO Annual Meeting; [5]Ray-Coquard et al., *N Engl J Med* 2019; [6]Coleman et al., *N Engl J Med* 2019; [7]Monk et al., 2022 ASCO Annual Meeting

Liu N. ASCO 2022;Highlights of the Day: Gynecologic Cancers.

Trials of 1L PARPi maintenance in ovarian cancer

Trial	PARP inhibitor	Duration	All comers	BRCAmt	BRCAwt overall	BRCAwt – HRD	BRCAwt – HRP	HRD assay
ATHENA-MONO[1]	Rucaparib	2 years	**HR 0.52** 20.2 vs 9.2 mos	**HR 0.40** NR vs 14.7 mos	--	**HR 0.58** 95%CI 0.33-1.01 20.3 vs 9.2 mos	**HR 0.65** 95%CI 0.45-0.95 12.1 vs 9.1 mos	Foundation One CDx
SOLO1[2,3]	Olaparib	2 years	--	**HR 0.33** 56.0 vs 13.8 mos	--	--	--	--
PRIMA[4]	Niraparib	3 years	**HR 0.62** 13.8 vs 8.2 mos	**HR 0.40** 22.1 vs 10.9 mos	--	**HR 0.50** 19.6 vs 8.2 mos	**HR 0.68** 8.1 vs 5.4 mos	Myriad MyChoice
PRIME[5]	Niraparib	3 years	**HR 0.45** 24.8 vs 8.3 mos	**HR 0.40** NR vs 10.8 mos	**HR 0.48*** 19.3 vs 8.3 mos	**HR 0.58** 24.8 vs 11.1 mos	**HR 0.41** 14.0 vs 5.5 mos	Not published
PAOLA1[6]	Olaparib (w/bevacizumab)	2 years	**HR 0.59** 22.1 vs 16.6 mos	**HR 0.31** 37.2 vs 21.7 mos	**HR 0.71** 18.9 vs 16.0 mos	**HR 0.43** 28.1 vs 16.6 mos	**HR 0.92 (NS)** 18.9 vs 16.0 mos	Myriad MyChoice
VELIA[7]	Veliparib (w/chemo)	36 total cycles	**HR 0.68** 23.5 vs 17.3 mos	**HR 0.44** 34.7 vs 22.0 mos	**HR 0.80** 18.2 vs 15.1 mos	**HR 0.74 (NS)** 15.0 vs 11.5 mos	**HR 0.81 (NS)** 18.2 vs 15.1 mos	Myriad MyChoice

*does not exclude pts with sBRCAmt tumors

[1]Monk et al., 2022 ASCO Annual Meeting; [2]Moore et al., *N Engl J Med* 2018; [3]Banerjee et al., 2020 ESMO Congress; [4]Gonzalez-Martin et al., *N Engl J Med* 2019; [5]Li et al., 2022 SGO Annual Meeting; [6]Ray-Coquard et al., *N Engl J Med* 2019; [7]Coleman et al., *N Engl J Med* 2019

Liu N. ASCO 2022;Highlights of the Day: Gynecologic Cancers.

original reports

A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)

Bradley J. Monk, MD[1]; Christine Parkinson, MD[2]; Myong Cheol Lim, MD, PhD[3]; David M. O'Malley, MD[4]; Ana Oaknin, MD, PhD[5]; Michelle K. Wilson, MD[6]; Robert L. Coleman, MD[7]; Domenica Lorusso, MD, PhD[8]; Paul Bessette, MD[9]; Sharad Ghamande, MD[10]; Athina Christopoulou, MD, PhD[11]; Diane Provencher, MD[12]; Emily Prendergast, MD[13]; Fuat Demirkiran, MD[14]; Olga Mikheeva, MD[15]; Oladapo Yeku, MD, PhD[16]; Anita Chudecka-Glaz, MD, PhD[17]; Michael Schenker, MD, PhD[18]; Ramey D. Littell, MD[19]; Tamar Safra, MD[20]; Hung-Hsueh Chou, MD[21,22]; Mark A. Morgan, MD[23]; Vít Drochýtek, MD[24]; Joyce N. Barlin, MD[25]; Toon Van Gorp, MD[26]; Fred Ueland, MD[27]; Gabriel Lindahl, MD[28,29]; Charles Anderson, MD[30]; Dearbhaile C. Collins, MBBCh, MA, PhD[31]; Kathleen Moore, MD[32]; Frederik Marme, MD, PhD[33]; Shannon N. Westin, MD, MPH[34]; Iain A. McNeish, MD, PhD[35]; Danny Shih, BA[36]; Kevin K. Lin, PhD[37]; Sandra Goble, MS[38]; Stephanie Hume, PhD[39]; Keiichi Fujiwara, MD, PhD[40]; and Rebecca S. Kristeleit, MD, PhD[41]

J Clin Oncol 2022;[Online ahead of print].

ATHENA-MONO: Investigator-Assessed PFS







Monk BJ et al. *J Clin Oncol* 2022;[Online ahead of print].

Case Presentation: 38-year-old woman with Stage IIC BRCA WT HGSOC s/p surgery and carboplatin/paclitaxel – LOH-negative

Dr Dana Chase (Phoenix, Arizona)

RTP
RESEARCH
TO PRACTICE

Case Presentation: 62-year-old woman with Stage IIIC HGSOC and a gBRCA1 mutation receives IV/IP paclitaxel/cisplatin

Dr Paul DiSilvestro (Providence, Rhode Island)

RTP
RESEARCH
TO PRACTICE

Case Presentation: 60-year-old woman with BRCA WT, HRD-negative peritoneal cancer s/p neo/adjuvant carboplatin/paclitaxel presents with altered mental status and a cerebellar metastasis

Dr Karim ElSahwi (Neptune City, New Jersey)

RTP
RESEARCH
TO PRACTICE



Case Presentation: 72-year-old woman with multiregimen-recurrent endometrioid ovarian adenocarcinoma with a gPALB2 mutation develops breast cancer during maintenance niraparib

Dr Dana Chase (Phoenix, Arizona)

RTP
RESEARCH
TO PRACTICE

OReO/ENGOT Ov-38 Trial: Impact of Maintenance Olaparib Rechallenge According to Ovarian Cancer Patient Prognosis — An Exploratory Joint Analysis of the BRCA and Non-BRCA Cohorts

Selle F et al.

ASCO 2022;Abstract 5558.

OReO: Post-hoc Analysis of Progression-Free Survival According to Patient Characteristics and Prognostic Factors

Subgroup	Events/N olaparib	Events/N placebo	Hazard ratio (95% CI)	Interaction
Age				0.89
<65	66/84	40/43	0.53 (0.35–0.80)	
≥65	47/62	28/31	0.54 (0.33–0.87)	
Genomic BRCAm and HRD status				0.93
BRCAwt HRD negative	18/31	8/11	0.49 (0.20–1.19)	
BRCAm	65/74	38/38	0.58 (0.38–0.88)	
BRCAwt HRD positive	21/28	13/16	0.53 (0.26–1.09)	
BRCAwt HRD unknown	9/13	9/9	0.44 (0.17–1.18)	
CA-125				0.19
<35	79/104	43/48	0.45 (0.30–0.67)	
≥35	31/39	24/25	0.86 (0.50–1.48)	
ECOG performance status				0.59
0	84/108	44/47	0.57 (0.39–0.83)	
1	29/38	24/27	0.50 (0.28–0.88)	
Visceral site of metastatic disease				0.07
N	71/99	55/60	0.41 (0.29–0.60)	
Y	42/47	13/14	0.87 (0.46–1.64)	
All patients	113/146	68/74	0.54 (0.39–0.73)	



- Olaparib rechallenge was effective regardless of prognostic subgroup
- CA-125 levels and the presence of visceral disease at baseline were the best predictors of patient outcome

Selle F et al. ASCO 2022;Abstract 5558.

RTP RESEARCH TO PRACTICE

Case Presentation: 76-year-old woman with Stage IV ovarian cancer goes for debulking surgery after carboplatin/paclitaxel and maintenance niraparib

Dr Bruce Bank (Rolling Meadows, Illinois)

RTP
RESEARCH
TO PRACTICE

Case Presentation: 69-year-old woman with Stage IV BRCA WT, HRD-negative HGSOC develops anemia on maintenance olaparib/bevacizumab

Dr Priya Rudolph (Athens, Georgia)

RTP
RESEARCH
TO PRACTICE

Case Presentation: 57-year-old woman (s/p donor nephrectomy) with Stage IIIA HGSOC, gBRCA1 mutant

Dr Paul DiSilvestro (Providence, Rhode Island)

RTP
RESEARCH
TO PRACTICE

Case Presentation: 59-year-old woman with primary peritoneal cancer, gBRCA1 mutant, develops a small pelvic recurrence after neo/adjuvant chemotherapy and surgery

Dr Karim ElSahwi (Neptune City, New Jersey)

RTP
RESEARCH
TO PRACTICE


Before
After
0.00
50 % PET
3.3

Case Presentation: 53-year-old woman with locally recurrent ovarian cancer (BRCA WT) develops lymphedema on maintenance bevacizumab/niraparib

Dr Gigi Chen (Pleasant Hill, California)

Meet The Professor with Dr Penson

Introduction: Journal Club with Dr Penson – Part 1

MODULE 1: Case Presentations

MODULE 2: Faculty Survey

MODULE 3: Journal Club with Dr Penson – Part 2

MODULE 4: Appendix of Key Publications

RTP
RESEARCH
TO PRACTICE

A patient presenting with ovarian cancer with extensive intra-abdominal disease (clinical Stage IIIC) receives neoadjuvant carboplatin/paclitaxel/ bevacizumab with good response and proceeds to surgery with R0 resection. Regulatory and reimbursement issues aside, what would be your preferred approach to maintenance therapy if genetic testing revealed a germline BRCA mutation?

 Dr Eskander	Olaparib/bevacizumab	 Dr Matulonis	Olaparib/bevacizumab
 Prof Ledermann	Olaparib/bevacizumab	 Dr Penson	Olaparib
 Dr Lheureux	Olaparib/bevacizumab	 Dr Westin	Olaparib/bevacizumab

RTP RESEARCH TO PRACTICE

A patient presenting with ovarian cancer with extensive intra-abdominal disease (clinical Stage IIIC) receives neoadjuvant carboplatin/paclitaxel/ bevacizumab with good response and proceeds to surgery with R0 resection. Genetic testing revealed a germline BRCA mutation. Beyond your preferred approach, which other approaches to maintenance therapy do you believe are acceptable in this situation?

 Dr Eskander	Niraparib Olaparib Rucaparib	 Dr Matulonis	Niraparib
 Prof Ledermann	Niraparib Olaparib Rucaparib	 Dr Penson	Niraparib Olaparib Rucaparib
 Dr Lheureux	Niraparib Olaparib Rucaparib	 Dr Westin	Niraparib Olaparib Rucaparib

RTP RESEARCH TO PRACTICE

A patient presenting with Stage IIIC ovarian cancer undergoes R0 resection and receives adjuvant carboplatin/paclitaxel with good response. Regulatory and reimbursement issues aside, what would you most likely recommend as maintenance therapy if genetic testing revealed BRCA wild type, HR proficient (eg, LOH low)?

 Dr Eskander	Niraparib	 Dr Matulonis	None Bevacizumab
 Prof Ledermann	Bevacizumab	 Dr Penson	Niraparib
 Dr Lheureux	Niraparib	 Dr Westin	Niraparib

RTP
RESEARCH
TO PRACTICE

A patient presenting with Stage IIIC ovarian cancer undergoes R0 resection and receives adjuvant carboplatin/paclitaxel with good response. Regulatory and reimbursement issues aside, what would you most likely recommend as maintenance therapy if genetic testing revealed a germline PALB2 mutation?

 Dr Eskander	Olaparib	 Dr Matulonis	Niraparib
 Prof Ledermann	None	 Dr Penson	Olaparib
 Dr Lheureux	Niraparib	 Dr Westin	Olaparib

RTP RESEARCH TO PRACTICE

A patient presenting with Stage IIIC ovarian cancer undergoes R0 resection and receives adjuvant carboplatin/paclitaxel with good response. Regulatory and reimbursement issues aside, what would you most likely recommend as maintenance therapy if genetic testing revealed a somatic BRCA mutation?

 Dr Eskander	Olaparib	 Dr Matulonis	Olaparib
 Prof Ledermann	Olaparib	 Dr Penson	Olaparib
 Dr Lheureux	Olaparib	 Dr Westin	Olaparib

RTP RESEARCH TO PRACTICE

A patient presenting with Stage IIIC ovarian cancer undergoes R0 resection and receives adjuvant carboplatin/paclitaxel with good response. Regulatory and reimbursement issues aside, what would you most likely recommend as maintenance therapy if genetic testing revealed BRCA wild type, HR deficient (eg, LOH high)?

 Dr Eskander	Niraparib	 Dr Matulonis	Niraparib
 Prof Ledermann	Olaparib/bevacizumab	 Dr Penson	Niraparib
 Dr Lheureux	Niraparib	 Dr Westin	Niraparib

RTP RESEARCH TO PRACTICE

Meet The Professor with Dr Penson

Introduction: Journal Club with Dr Penson – Part 1

MODULE 1: Case Presentations

MODULE 2: Faculty Survey

MODULE 3: Journal Club with Dr Penson – Part 2

MODULE 4: Appendix of Key Publications

RTP
RESEARCH
TO PRACTICE

Phase II Study of Olaparib plus Durvalumab with or without Bevacizumab (MEDIOLA): Final Analysis of Overall Survival in Patients with Non-Germline BRCA-Mutated Platinum-Sensitive Relapsed Ovarian Cancer

Banerjee S et al.

ESMO 2022;Abstract 529MO.

Mini Oral Session 2: Gynaecological Cancers

September 11, 2022

Abstract 5559
Poster 438

ASCO 2022

BRCA reversion mutations mediated by MMEJ as a mechanism of resistance to PARP inhibitors

Natalia Lukashchuk,[1] Joshua Armenia,[1] Luis Tobalina,[1] T. Hedley Carr,[1] Tsveta Milenkova,[2] Ying L. Liu,[3] Richard T. Penson,[4] Mark E. Robson,[5] Elizabeth A. Harrington[1]

JC JOURNAL CLUB RTP RESEARCH TO PRACTICE

SGO 2022;Abstract 25.

Final overall survival results from SOLO3: Phase III trial assessing olaparib monotherapy versus non-platinum chemotherapy in heavily pre-treated patients with germline *BRCA1*- and/or *BRCA2*-mutated platinum-sensitive relapsed ovarian cancer

Richard T Penson MD,[1] Ricardo Villalobos Valencia MD,[2] Nicoletta Colombo MD,[3] Charles A Leath III MD,[4] Mariusz Bidzinski MD,[5] Jae-Weon Kim MD,[6] Joo-Hyun Nam MD,[7] Radoslaw Madry MD,[8] Carlos Hernández MD,[9] Paulo Mora MD,[10] Sang Young Ryu MD,[11] Tsveta Milenkova MD,[12] Elizabeth S Lowe MD,[13] Natalia Lukashchuk PhD,[12] John McNamara MSc,[12] Giovanni Scambia MD[14]

[1]Massachusetts General Hospital, Boston, MA, USA; [2]Centro Medico Dalinde, Mexico City, Mexico; [3]University of Milan-Bicocca and IEO European Institute of Oncology IRCCS, Milan, Italy; [4]O'Neal Comprehensive Cancer Center, University of Alabama, Birmingham, AL, USA; [5]Faculty of Medicine and Health Sciences, Jan Kochanowski University, Kielce, Poland; [6]Seoul National University Hospital, Seoul, South Korea; [7]Asan Medical Center, Seoul, South Korea; [8]Uniwersytet Medyczny im. K. Marcinkowskiego w Poznaniu and Szpital Kliniczny Przemienienia Pańskiego, Poznań, Poland; [9]Oaxaca Site Management Organization, Oaxaca de Juarez, Mexico; [10]Instituto COI de Educação e Pesquisa, Rio de Janeiro, Brazil; [11]Korea Institute of Radiological and Medical Sciences, Seoul, South Korea; [12]AstraZeneca, Cambridge, UK; [13]AstraZeneca, Gaithersburg, MD, USA; [14]Università Cattolica del Sacro Cuore-Fondazione Policlinico A. Gemelli, IRCCS, Rome, Italy

ClinicalTrials.gov identifier: NCT02282020. This study was sponsored by AstraZeneca and is part of an alliance between AstraZeneca and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA

ANNUAL MEETING ON WOMENS' CANCER®
BUILDING BRIDGES // BREAKING BARRIERS
SGO // PHOENIX, ARIZONA // MARCH 18 - 21, 2022

SGO Society of Gynecologic Oncology

ctDNA BRCA Reversion Mutations Detected at Baseline

BRCA reversion mutations in ctDNA* detected in 6/170 evaluable patients (3.5%) at baseline

BRCA2 protein



- All *BRCA* reversion mutations identified at study baseline were in the *BRCA2* gene‡
- Patients had single or multiple reversion mutations with an allelic frequency of 0.2–8%

ANNUAL MEETING ON WOMENS' CANCER®
BUILDING BRIDGES // BREAKING BARRIERS
SGO // PHOENIX, ARIZONA // MARCH 18 - 21, 2022

*Data from targeted ctDNA sequencing;
†Each color represents an individual patient;
‡Reversion mutations can happen in both *BRCA1* and *BRCA2*

Society of Gynecologic Oncology

Penson RT et al. SGO 2022;Abstract 25.

JC JOURNAL CLUB
RTP RESEARCH TO PRACTICE

Best Response to Olaparib in Patients with BRCA Reversions Identified at Baseline – Stable or Progressive Disease*



	Baseline characteristics in the olaparib arm	
	Patients with baseline *BRCA* reversions (n=6)	Patients without baseline *BRCA* reversions (n=111)
Number of previous chemotherapy regimens, n (%)		
2	1 (17)	59 (53)
3	0	25 (23)
≥4	5 (83)	27 (24)
Median (range) duration of previous chemotherapy, days	840 (265–1451)	427 (84–2800)

ANNUAL MEETING ON WOMENS' CANCER®
BUILDING BRIDGES // BREAKING BARRIERS
SGO // PHOENIX, ARIZONA // MARCH 18 – 21, 2022

*No partial or complete responses were seen in patients with *BRCA* reversions identified at baseline prior to olaparib treatment. No baseline *BRCA* reversions were found in the chemotherapy arm;
†*BRCA* reversions at baseline

Society of Gynecologic Oncology

Penson RT et al. SGO 2022;Abstract 25.

JC JOURNAL CLUB
RTP RESEARCH TO PRACTICE

Gynecologic Oncology 165 (2022) 40–48

Contents lists available at ScienceDirect

Gynecologic Oncology

journal homepage: www.elsevier.com/locate/ygyno



Efficacy and safety of olaparib according to age in *BRCA1/2*-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study

Fabian Trillsch [a,*], Sven Mahner [a], Beyhan Ataseven [a,b], Rebecca Asher [c], Nanda Aryal [c], Coraline Dubot [d], Andrew Clamp [e], Richard T. Penson [f], Amit Oza [g], Amnon Amit [h], Tomasz Huzarski [i], Antonio Casado [j], Giovanni Scambia [k], Michael Friedlander [l], Nicoletta Colombo [m], Keiichi Fujiwara [n], Gabe S. Sonke [o], Hannelore Denys [p], Elizabeth S. Lowe [q], Chee K. Lee [c], Eric Pujade-Lauraine [r]

Expert Opinion on Drug Safety 2022;21(4):447-51.

ISSN: (Print) (Online) Journal homepage: https://www.tandfonline.com/loi/ieds20

An update on the safety of olaparib for treating ovarian cancer

Kelsi Cottrell, Caroline L. Clark & Richard T. Penson

A First-in-Human Study of AO-176, a Highly Differentiated Anti-CD47 Antibody, in Patients with Advanced Solid Tumors

Burris HA et al.

ASCO 2021;Abstract 2516.

Meet The Professor with Dr Penson

Introduction: Journal Club with Dr Penson – Part 1

MODULE 1: Case Presentations

MODULE 2: Faculty Survey

MODULE 3: Journal Club with Dr Penson – Part 2

MODULE 4: Appendix of Key Publications

RTP
RESEARCH
TO PRACTICE

Optimal Biomarker Evaluation and Front-Line Management

Ovarian cancer 1L PARPi maintenance trials: design and populations

Trial	PARP inhibitor	Duration	BRCA status	R0 at PDS allowed	% PDS	CR/PR to platinum
SOLO1[1,2]	Olaparib	2 years	*BRCA*mt only	Yes	62.9	Yes
PRIMA[3]	Niraparib	3 years	All comers	No if Stage III	33	Yes
PRIME[4]	Niraparib	3 years	All comers	Yes	53.1	Yes
PAOLA1[5]	Olaparib (w/bevacizumab)	2 years	All comers	Yes	50.7	Yes
VELIA[6]	Veliparib (w/chemo)	36 total cycles	All comers	Yes	67.5	No (tx starts with chemo)
ATHENA-MONO[7]	Rucaparib	2 years	All comers	Yes	48.9	Yes

[1]Moore et al., *N Engl J Med* 2018; [2]Banerjee et al., 2020 ESMO Congress; [3]Gonzalez-Martin et al., *N Engl J Med* 2019; [4]Li et al., 2022 SGO Annual Meeting; [5]Ray-Coquard et al., *N Engl J Med* 2019; [6]Coleman et al., *N Engl J Med* 2019; [7]Monk et al., 2022 ASCO Annual Meeting

Liu N. ASCO 2022;Highlights of the Day: Gynecologic Cancers.

Trials of 1L PARPi maintenance in ovarian cancer

Trial	PARP inhibitor	Duration	All comers	BRCAmt	BRCAwt overall	BRCAwt – HRD	BRCAwt – HRP	HRD assay
ATHENA-MONO[1]	Rucaparib	2 years	**HR 0.52** 20.2 vs 9.2 mos	**HR 0.40** NR vs 14.7 mos	--	**HR 0.58** 95%CI 0.33-1.01 20.3 vs 9.2 mos	**HR 0.65** 95%CI 0.45-0.95 12.1 vs 9.1 mos	Foundation One CDx
SOLO1[2,3]	Olaparib	2 years	--	**HR 0.33** 56.0 vs 13.8 mos	--	--	--	--
PRIMA[4]	Niraparib	3 years	**HR 0.62** 13.8 vs 8.2 mos	**HR 0.40** 22.1 vs 10.9 mos	--	**HR 0.50** 19.6 vs 8.2 mos	**HR 0.68** 8.1 vs 5.4 mos	Myriad MyChoice
PRIME[5]	Niraparib	3 years	**HR 0.45** 24.8 vs 8.3 mos	**HR 0.40** NR vs 10.8 mos	**HR 0.48*** 19.3 vs 8.3 mos	**HR 0.58** 24.8 vs 11.1 mos	**HR 0.41** 14.0 vs 5.5 mos	Not published
PAOLA1[6]	Olaparib (w/bevacizumab)	2 years	**HR 0.59** 22.1 vs 16.6 mos	**HR 0.31** 37.2 vs 21.7 mos	**HR 0.71** 18.9 vs 16.0 mos	**HR 0.43** 28.1 vs 16.6 mos	**HR 0.92 (NS)** 18.9 vs 16.0 mos	Myriad MyChoice
VELIA[7]	Veliparib (w/chemo)	36 total cycles	**HR 0.68** 23.5 vs 17.3 mos	**HR 0.44** 34.7 vs 22.0 mos	**HR 0.80** 18.2 vs 15.1 mos	**HR 0.74 (NS)** 15.0 vs 11.5 mos	**HR 0.81 (NS)** 18.2 vs 15.1 mos	Myriad MyChoice

*does not exclude pts with sBRCAmt tumors

[1]Monk et al., 2022 ASCO Annual Meeting; [2]Moore et al., *N Engl J Med* 2018; [3]Banerjee et al., 2020 ESMO Congress; [4]Gonzalez-Martin et al., *N Engl J Med* 2019; [5]Li et al., 2022 SGO Annual Meeting; [6]Ray-Coquard et al., *N Engl J Med* 2019; [7]Coleman et al., *N Engl J Med* 2019

Liu N. ASCO 2022;Highlights of the Day: Gynecologic Cancers.

Pivotal Trials and Regulatory Milestones in First-Line Maintenance Therapy for Advanced Ovarian Cancer



Dates shown indicate the year of the publication of the pivotal studies and regulatory approvals for these compounds.

*BRCA*m, breast cancer gene mutant; GOG, Gynecologic Oncology Group; Pt, platinum.

1. Burger RA et al. *N Engl J Med*. 2011;365(26):2473-2483. 2. Perren TJ et al. *N Engl J Med*. 2011;365(26):2484-2496. 3. Moore K et al. *N Engl J Med*. 2018;379(26):2495-2505. 4. González-Martín A et al. *N Engl J Med*. 2019;381(25):2391-2402. . Ray-Coquard I et al. *N Engl J Med*. 2019;381(25):2416-2428. 6. Coleman RL et al. *N Engl J Med*. 2019;381(25):2403-2415. 7. European Medicines Agency. Published September 22, 2011. Accessed June 7, 2021. 8. F. Hoffmann-La Roche Ltd. Published June 13, 2018. Accessed June 7, 2021. 9. US Food and Drug Administration. Published December 26, 2018. Accessed June 7, 2021. 10. European Medicines Agency. Published April 26, 2019. Accessed June 7, 2021. 11. GlaxoSmithKline. Published April 29, 2020. Accessed June 7, 2021. 12. GlaxoSmithKline. Published October 29, 2020. Accessed June 7, 2021. 13. US Food and Drug Administration. Published May 11, 2020. Accessed June 7, 2021. 14. European Medicines Agency. Published September 17, 2020. Accessed June 7, 2021.

Courtesy of Kathleen Moore, MD

RTP RESEARCH TO PRACTICE

Phase III First-Line PARP Inhibitor Maintenance Trials

Study design	SOLO-1[1] (N = 391)	PAOLA-1[2] (N = 612)	PRIMA[3] (N = 620)	VELIA[4] (N = 1,140)
Treatment arms vs placebo	**Olaparib (n=260)**	**Bevacizumab ± olaparib**	**Niraparib**	**Veliparib**
Patient population	*BRCA* mutation	All comers	All comers	All comers
Treatment duration	24 mo	15 mo for bev 24 mo for olaparib	36 mo or until PD	24 mo
Median PFS	56 mo vs 14 mo HR: 0.33	22.1 mo vs 16.6 mo HR: 0.59	22.1 mo vs 10.9 mo HR 0.40	23.5 mo vs 17.3 mo HR: 0.68

bev = bevacizumab; PD = disease progression

[1] Banerjee et al. *Lancet Oncol* 2021;22(12):1721-31; [2] Ray-Coquard et al. SGO 2020;Abstract 33; [3] González-Martín A et al. ASCO 2021;Abstract 5518; [4] Aghajanian C et al. *Gyn Oncol* 2021;162(2):375-81.

Phase 2 OVARIO Study of Niraparib + Bevacizumab Therapy in Advanced Ovarian Cancer Following Frontline Platinum-Based Chemotherapy with Bevacizumab

Melissa M. Hardesty,[1] Thomas Krivak,[2] Gail S. Wright,[3] Erika Hamilton,[4] Evelyn L. Fleming,[5] Jimmy Belotte,[6] Erika Keeton,[6] Ping Wang,[6] Aine Clements,[7] Heidi J. Gray,[8] Gottfried E. Konecny,[9] Richard G. Moore,[10] Debra L. Richardson[11]

[1]Alaska Women's Cancer Care, Anchorage, AK, USA; [2]Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Western Pennsylvania Hospital, Pittsburgh, PA, USA; [3]Florida Cancer Specialists and Research Institute, New Port Richey, FL, USA; [4]Sarah Cannon Research Institute; Tennessee Oncology, Nashville, TN, USA; [5]Division of Gynecologic Oncology, Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA; [6]GlaxoSmithKline, Waltham, MA, USA; [7]Department of Gynecologic Oncology, Riverside Methodist Hospital, Columbus, OH, USA; [8]Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington, Seattle, WA, USA; [9]University of California Los Angeles, Los Angeles, CA, USA; [10]Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA; [11]Division of Gynecologic Oncology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA

ANNUAL MEETING ON WOMENS' CANCER
BUILDING BRIDGES // BREAKING BARRIERS
SGO // PHOENIX, ARIZONA // MARCH 19 - 21, 2022

Society of Gynecologic Oncology

SGO 2022;Abstract 40.

RTP RESEARCH TO PRACTICE

Patients with newly diagnosed high-grade serous or endometrioid stage IIIB to IV epithelial ovarian, fallopian tube, or peritoneal cancer who achieved a CR, PR, or NED result after front-line platinum-based chemotherapy + bevacizumab

All patients underwent tissue testing for HRd at enrollment

Niraparib (200 or 300 mg QD) + bevacizumab (15 mg/kg Q3W)

Starting niraparib dose, n (%)	N=105
200 mg (<77 kg and/or platelet count <150,000/µL)	82 (78)
300 mg (all others)	23 (22)

Endpoint assessment

Primary endpoint	• PFS rate at 18 months (PFS18)
Secondary endpoints	• PFS • Overall survival • RECIST or CA-125 PFS • Time to first subsequent therapy • Time to second subsequent therapy • Safety and tolerability • Patient-reported outcome
Exploratory endpoints	• PFS rate at 6 months (PFS6) and 12 months (PFS12)
Statistical analysis plan	• Efficacy: PFS18 and PFS24 will be estimated by frequency analysis, with corresponding 95% exact CI will be reported • The time to event endpoints (PFS, TFST, TSST) will be analyzed using Kaplan-Meier methodology • Progression will be assessed by RECIST v1.1 per investigator

Hardesty et al. SGO 2022;Abstract 40.

OVARIO: PFS by Homologous Recombination Deficiency Status



Overall (n = 105)	
18-mo PFS rate	62
24-mo PFS rate	53

HRd (n = 49)	
18-mo PFS rate	76
24-mo PFS rate	63

HRp (n = 38)	
18-mo PFS rate	47
24-mo PFS rate	42

HRnd (n = 18)	
18-mo PFS rate	56
24-mo PFS rate	50

Hardesty et al. SGO 2022;Abstract 40.

OVARIO: Treatment-Related Adverse Events (TRAEs)

Parameter, n (%)	N=105		
	Related to nira or bev	Related to nira	Related to bev
Any TRAE	105 (100)	104 (99)	96 (91)
Any Grade ≥3 TRAE	84 (80)	81 (77)	54 (51)
Any serious TRAE	21 (20)	19 (18)	7 (7)
TRAE leading to treatment discontinuation	42 (40)	32 (30)	23 (22)
TRAE leading to dose reduction	78 (74)	77 (73)	27 (26)
TRAE leading to treatment interruption	93 (88)	90 (86)	58 (55)

TRAEs in ≥20% of patients (N=105) Related to niraparib or bevacizumab		
Preferred term, n (%)	Any Grade	Grade ≥3
Thrombocytopenia[a]	74 (70)	41 (39)
Fatigue	60 (57)	9 (9)
Anemia[b]	55 (52)	36 (34)
Nausea	55 (52)	1 (1)
Hypertension[c]	53 (50)	28 (27)
Proteinuria	41 (39)	5 (5)
Headache	32 (30)	6 (6)
Neutropenia[d]	28 (27)	13 (12)
Leukopenia[e]	24 (23)	0

Hardesty et al. SGO 2022;Abstract 40.

Efficacy and Safety of Niraparib as Maintenance Treatment in Patients with Newly Diagnosed Advanced Ovarian Cancer Using an Individualized Starting Dose (PRIME Study): A Randomized, Double-blind, Placebo-controlled, Phase 3 Trial

Ning Li*, Jianqing Zhu, Rutie Yin, Jing Wang, Lingya Pan, Beihua Kong, Hong Zheng, Jihong Liu, Xiaohua Wu, Li Wang, Yi Huang, Ke Wang, Dongling Zou, Hongqin Zhao, Chunyan Wang, Weiguo Lu, An Lin, Ge Lou, Guiling Li, Pengpeng Qu, Hongying Yang, Xiaoa Zhen, Wenzhao Hang, Jianmei Hou, Lingying Wu*

* National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

SGO 2022;Abstract LBA5.

PRIME: Study Design

PRIME is a randomized, double-blind, placebo-controlled phase III trial (NCT03709316).

Schema

Eligible Patients

- Age ≥18 years
- FIGO stage III/IV ovarian cancer
- High-grade serous or endometroid tumor[a]
- Receipt of primary or interval cytoreductive surgery, irrespective of postoperative residual disease status
- CR/PR to 1L Pt-based chemotherapy

Stratified randomization

- Status of g*BRCA* mutations (g*BRCA*mut/non-g*BRCA*mut)
- Tumor HRD status[b] (positive/negative)
- Receipt of neoadjuvant chemotherapy (Y/N)
- Response to 1L Pt-based chemotherapy (CR/PR)

2:1 Randomization

- **Niraparib***
- **Placebo***

36 months or until disease progression or unacceptable toxicity

*Individualised starting dose (ISD) was adopted in **ALL** patients: *starting dose of 200 mg administered orally, once daily, but 300 mg for patients with body weight ≥77 kg AND platelet count ≥150,000/μL*

Primary Endpoint

- **PFS by BICR in the ITT population**

Secondary Endpoints

- OS and TFST in the ITT population
- PFS and OS in the HRD subgroup[c]
- Safety

Li et al. SGO 2022;Abstract LBA5.

PRIME: Demographics and Baseline Characteristics

Characteristic	Niraparib (N=255)	Placebo (N=129)
Median age (range), years	53.0 (32–77)	54.0 (33–77)
Median weight (range), kg	59.0 (39.5–100.0)	57.0 (37.0–97.0)
ECOG performance status, n (%)		
0	98 (38.4)	52 (40.3)
1	157 (61.6)	77 (59.7)
FIGO stage, n (%)		
III	182 (71.4)	94 (72.9)
IV	73 (28.6)	35 (27.1)
Primary tumor location, n (%)		
Ovary	229 (89.8)	117 (90.7)
Fallopian tube	19 (7.5)	9 (7.0)
Peritoneum	7 (2.7)	3 (2.3)
Histologic subtype, n (%)		
Serous ovarian cancer	253 (99.2)	128 (99.2)
Endometrioid carcinoma	2 (0.8)	0
Other	0	1 (0.8)

Characteristic	Niraparib (N=255)	Placebo (N=129)
Neoadjuvant chemotherapy, n (%)		
Yes	121 (47.5)	59 (45.7)
No	134 (52.5)	70 (54.3)
Response to Pt-based CT, n (%)		
CR	212 (83.1)	103 (79.8)
PR	43 (16.9)	26 (20.2)
g*BRCA* mutation status, n (%)		
g*BRCA*mut	85 (33.3)	40 (31.0)
Non-g*BRCA*mut	170 (66.7)	89 (69.0)
Homologous recombination[a], n (%)		
Deficient	170 (66.7)	87 (67.4)
Proficient	85 (33.3)	42 (32.6)
Postoperative residual disease status, n (%)		
Optimal (R0/R1)	193 (75.7)	105 (81.4)
Suboptimal (R2) or missing	52 (24.3)	24 (18.6)

- The niraparib and placebo groups were well-balanced.

Li et al. SGO 2022;Abstract LBA5.

PRIME: PFS (by Blinded Independent Central Review) in the ITT Population



16.5 months longer median PFS with niraparib versus placebo

	Niraparib (N=255)	Placebo (N=129)
PFS (54.4% data maturity)		
Events, n (%)	123 (48.2)	86 (66.7)
mPFS (95% CI), months	24.8 (19.2–NE)	8.3 (7.3–11.1)
Patients without PD or death (%)		
24 months	52.6	30.4

Li et al. SGO 2022;Abstract LBA5.

RTP RESEARCH TO PRACTICE

PRIME: PFS Benefit in Prespecified Subgroups

Subgroup	Events/patients (%)		Hazard ratio for PFS (95% CI)
	Niraparib	Placebo	
Overall	123/255 (48.2)	86/129 (66.7)	0.45 (0.34–0.60)
Age			
<65 years	108/229 (47.2)	73/114 (64.0)	0.47 (0.34–0.63)
≥65 years	15/26 (57.7)	13/15 (86.7)	0.24 (0.09–0.66)
Neoadjuvant chemotherapy			
Yes	62/121 (51.2)	46/59 (78.0)	0.32 (0.21–0.48)
No	61/134 (45.5)	40/70 (57.1)	0.63 (0.42–0.94)
Response to Pt-based chemotherapy			
Complete response	98/212 (46.2)	66/103 (64.1)	0.45 (0.32–0.61)
Partial response	25/43 (58.1)	20/26 (76.9)	0.45 (0.23–0.86)
***gBRCA* mutation status**			
*gBRCA*mut	35/85 (41.2)	25/40 (62.5)	0.40 (0.23–0.68)
Non-g*BRCA*mut	88/170 (51.8)	61/89 (68.5)	0.48 (0.34–0.67)
Homologous recombination			
Deficient	75/170 (44.1)	57/87 (65.5)	0.48 (0.34–0.68)
Proficient	48/85 (56.5)	29/42 (69.0)	0.41 (0.25–0.65)
Postoperative residual disease status			
Optimal	94/193 (48.7)	71/105 (67.6)	0.44 (0.32–0.61)
Suboptimal or missing	29/62 (46.8)	15/24 (62.5)	0.43 (0.21–0.87)



Li et al. SGO 2022;Abstract LBA5.

PRIME: PFS Benefit by Germline BRCA Mutation Status

g*BRCA*mut



	Niraparib (N=85)	Placebo (N=40)
mPFS (95% CI), months	NR (22.3–NE)	10.8 (8.3–19.3)

Non-g*BRCA*mut



	Niraparib (N=170)	Placebo (N=89)
mPFS (95% CI), months	19.3 (13.8–NE)	8.3 (5.6–11.2)

- Median PFS has not been yet reached for the g*BRCA*mut population.
- The benefit of niraparib in the non-g*BRCA*mut population is confirmed.

Li et al. SGO 2022;Abstract LBA5.

RTP RESEARCH TO PRACTICE

PRIME: PFS Benefit in Non-gBRCAmut Subgroups

Non-g*BRCA*mut/HRd



	Niraparib (N=85)	Placebo (N=47)
mPFS (95% CI), months	24.8 (14.0–NE)	11.1 (8.3–13.8)

Non-g*BRCA*mut/HRp



	Niraparib (N=85)	Placebo (N=42)
mPFS (95% CI), months	14.0 (11.9–NE)	5.5 (2.9–7.3)

Li et al. SGO 2022;Abstract LBA5.

RTP RESEARCH TO PRACTICE

PRIME and PRIMA Trials: Safety Overview

TEAEs, n (%)	PRIME		PRIMA[1]	
	Niraparib (N=255)	Placebo (N=129)	Niraparib (N=484)	Placebo (N=244)
Any TEAEs	253 (99.2)	121 (93.8)	478 (98.8)	224 (91.8)
Treatment-related	249 (97.6)	111 (86.0)	466 (96.3)	168 (68.9)
Grade≥3 TEAEs	139 (54.5)	23 (17.8)	341 (70.5)	46 (18.9)
Treatment-related	125 (49.0)	9 (7.0)	316 (65.3)	16 (6.6)
Serious TEAEs	48 (18.8)	11 (8.5)	156 (32.2)	32 (13.1)
Treatment-related	38 (14.9)	5 (3.9)	118 (24.4)	6 (2.5)
TEAEs leading to treatment interruption	160 (62.7)	25 (19.4)	385 (79.5)	44 (18.0)
TEAEs leading to dose reduction[b]	103 (40.4)	8 (6.2)	343 (70.9)	20 (8.2)
TEAEs leading to discontinuation	17 (6.7)	7 (5.4)	58 (12.0)	6 (2.5)
TEAEs leading to death	1 (0.4)	0	2 (0.4)	1 (0.4)

Li et al. SGO 2022;Abstract LBA5.

original reports

A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)

Bradley J. Monk, MD[1]; Christine Parkinson, MD[2]; Myong Cheol Lim, MD, PhD[3]; David M. O'Malley, MD[4]; Ana Oaknin, MD, PhD[5]; Michelle K. Wilson, MD[6]; Robert L. Coleman, MD[7]; Domenica Lorusso, MD, PhD[8]; Paul Bessette, MD[9]; Sharad Ghamande, MD[10]; Athina Christopoulou, MD, PhD[11]; Diane Provencher, MD[12]; Emily Prendergast, MD[13]; Fuat Demirkiran, MD[14]; Olga Mikheeva, MD[15]; Oladapo Yeku, MD, PhD[16]; Anita Chudecka-Glaz, MD, PhD[17]; Michael Schenker, MD, PhD[18]; Ramey D. Littell, MD[19]; Tamar Safra, MD[20]; Hung-Hsueh Chou, MD[21,22]; Mark A. Morgan, MD[23]; Vít Drochýtek, MD[24]; Joyce N. Barlin, MD[25]; Toon Van Gorp, MD[26]; Fred Ueland, MD[27]; Gabriel Lindahl, MD[28,29]; Charles Anderson, MD[30]; Dearbhaile C. Collins, MBBCh, MA, PhD[31]; Kathleen Moore, MD[32]; Frederik Marme, MD, PhD[33]; Shannon N. Westin, MD, MPH[34]; Iain A. McNeish, MD, PhD[35]; Danny Shih, BA[36]; Kevin K. Lin, PhD[37]; Sandra Goble, MS[38]; Stephanie Hume, PhD[39]; Keiichi Fujiwara, MD, PhD[40]; and Rebecca S. Kristeleit, MD, PhD[41]

J Clin Oncol 2022;[Online ahead of print].

ATHENA-MONO Study Schema



Monk BJ et al. ASCO 2022;Abstract LBA5500.

ATHENA-MONO: Investigator-Assessed PFS in the HRD Population (N = 234)



Monk BJ et al. *J Clin Oncol* 2022;[Online ahead of print].

ATHENA-MONO: Investigator-Assessed PFS in the ITT Population (N = 538)



Monk BJ et al. *J Clin Oncol* 2022;[Online ahead of print].

RTP RESEARCH TO PRACTICE

ATHENA-MONO: Investigator-Assessed PFS







Monk BJ et al. *J Clin Oncol* 2022;[Online ahead of print].

ATHENA-MONO: Investigator-Confirmed ORR

	HRD Population		ITT Population	
Response	**Rucaparib (n = 17)**	**Placebo (n = 5)**	**Rucaparib (n = 41)**	**Placebo (n = 11)**
Confirmed ORR per RECIST				
No.	10	1	20	1
% (95% CI)	58.8 (32.9 to 81.6)	20.0 (0.5 to 71.6)	48.8 (32.9 to 64.9)	9.1 (0.2 to 41.3)
CR, No. (%)	0	0	1 (2.4)	0
PR, No. (%)	10 (58.8)	1 (20.0)	19 (46.3)	1 (9.1)
Stable disease, No. (%)	6 (35.3)	2 (40.0)	10 (24.4)	4 (36.4)
Progressive disease, No. (%)	1 (5.9)	2 (40.0)	10 (24.4)	6 (54.5)
Not evaluable, No. (%)	0	0	1 (2.4)	0

ORR = objective response rate

Monk BJ et al. *J Clin Oncol* 2022;[Online ahead of print].

ATHENA-MONO: Common Treatment-Emergent Adverse Events

	Rucaparib (n = 425)		Placebo (n = 110)	
TEAE	**Any Grade**	**Grade ≥ 3**	**Any Grade**	**Grade ≥ 3**
At least one TEAE, No. (%)	411 (96.7)	257 (60.5)	102 (92.7)	25 (22.7)
Nausea	239 (56.2)	8 (1.9)	33 (30.0)	0
Asthenia/fatigue	237 (55.8)	21 (4.9)	41 (37.3)	1 (0.9)
Anemia/decreased hemoglobin	198 (46.6)	122 (28.7)	10 (9.1)	0
Increased ALT/AST	181 (42.6)	45 (10.6)	9 (8.2)	1 (0.9)
Neutropenia/neutrophil count decreased	118 (27.8)	62 (14.6)	8 (7.3)	1 (0.9)
Abdominal pain	106 (24.9)	2 (0.5)	31 (28.2)	2 (1.8)
Diarrhea	102 (24.0)	6 (1.4)	23 (20.9)	1 (0.9)
Thrombocytopenia/platelet count decreased	101 (23.8)	30 (7.1)	1 (0.9)	0
Vomiting	100 (23.5)	6 (1.4)	13 (11.8)	0
Dysgeusia	90 (21.2)	1 (0.2)	6 (5.5)	0
Arthralgia	86 (20.2)	1 (0.2)	25 (22.7)	0
Headache	85 (20.0)	2 (0.5)	16 (14.5)	0

Monk BJ et al. *J Clin Oncol* 2022;[Online ahead of print].

FDA Advises Manufacturer Not to Submit First-Line Maintenance sNDA for Rucaparib Until OS Survival Data from the ATHENA-MONO Trial Are More Mature

June 17, 2022

"In consultation with the FDA, [the manufacturer of rucaparib] recently was advised not to file a supplemental new drug application based on data from a cohort of the Phase III ATHENA study until the study's overall survival data mature.

In the 8-K, [the manufacturer] said the FDA has accepted a request for a pre-NDA meeting and noted that the ATHENA-MONO portion of the Phase III study has met its primary endpoint of progression-free survival compared to placebo. OS is a secondary endpoint for ATHENA-MONO and the data are approximately 25% mature at present. [The manufacturer] said the FDA urged it to hold off filing for supplemental approval until the OS data reach 50% maturity, and indicated an advisory committee review would likely be necessary if the data were filed earlier than that point.

In a statement to *Scrip*, the firm said that although it cannot anticipate the outcome of the pre-NDA meeting, 'we are encouraged that the FDA is willing to have a dialogue.' [They] estimate the ATHENA-MONO OS data will reach 50% maturity in approximately two years."

https://scrip.pharmaintelligence.informa.com/SC146575/Clovis-Withdraws-Rubraca-Ovarian-Cancer-Indication-Due-To-Survival-Imbalance?vid=Pharma

RTP RESEARCH TO PRACTICE

ATHENA-MONO and ATHENA-COMBO Study Design



Monk BJ et al. *Int J Gynecol Cancer* 2021;31(12):1589-94.

DUO-O Study Design in Newly Diagnosed Advanced Ovarian Cancer



*Olaparib administered for a maximum of 24 months after chemotherapy. Durvalumab and bevacizumab administered for a maximum of 15 months

Estimated completion date: July 2023

Harter P et al. ASCO 2019;Abstract TPS5598; www.clinicaltrials.gov (NCT03737643) Accessed July 2022.

RTP RESEARCH TO PRACTICE

FIRST Phase III Trial of Dostarlimab (TSR-042) for Newly Diagnosed Ovarian Cancer



www.clinicaltrials.gov/ct2/show/NCT03602859

Courtesy of Ursula Matulonis, MD

Current Treatment Paradigm for Recurrent Disease

Ongoing Research with PARP Inhibitors for Newly Diagnosed and Relapsed Disease

Eligibility and Dosing in Pivotal Studies of PARP Inhibitors for Recurrent, Platinum-Sensitive Ovarian Cancer

	NOVA[1] (niraparib)	SOLO-2[2] (olaparib)	ARIEL3[3] (rucaparib)
BRCA status	With or without gBRCA mutation	gBRCA mutation (Study 19: +/- gBRCA mutation)	With or without gBRCA mutation
HRD testing	Yes	No	Yes
Tumor assessment schedule	Every 8 wk to C14 → every 12 wk	Every 12 wk until wk 72 → every 24 wk	Every 8 wk to C14 → every 12 wk
Dosing/formulation	300 mg qd	300 mg BID	600 mg BID
No. of prior lines of chemo	2 or more	2 or more	2 or more

[1] Mirza MR et al. *N Engl J Med* 2016;375(22):2154-64; [2] Pujade-Lauraine E et al. *Lancet* 2017;18(9):1274-84; [3] Coleman RL et al. *Lancet* 2017;390(10106):1949-61.

Progression-Free Survival with PARP Inhibitors for Recurrent, Platinum-Sensitive Ovarian Cancer

	PARPi	Control	HR
NOVA[1-2] — niraparib			
gBRCA mutation	21.0 mo	5.5 mo	0.27
No gBRCA mutation, HRD+	12.9 mo	3.8 mo	0.38
No gBRCA mutation	9.3 mo	3.9 mo	0.45
SOLO-2[3-4] — olaparib			
gBRCA mutation	19.1 mo	5.5 mo	0.30
Overall survival	51.7 mo	38.8 mo	0.74
ARIEL3[5-6] — rucaparib			
ITT (all comers)	10.8 mo	5.4 mo	0.36
g or sBRCA mutation	16.6 mo	5.4 mo	0.23
HRD+	13.6 mo	5.4 mo	0.32
$BRCA^{WT}$/high LOH	13.6 mo	5.4 mo	0.32
$BRCA^{WT}$/low LOH	6.7 mo	5.4 mo	0.58

[1] Mirza MR et al. *N Engl J Med* 2016;375(22):2154-64; [2] Del Campo JM et al. *J Clin Oncol* 2019;37(32):2968-73. [3] Poveda A et al. *Lancet Oncol* 2021;22(5):620-31. [4] Pujade-Lauraine E et al. *Lancet* 2017;18(9):1274-84; [5] Coleman RL et al. *Lancet* 2017;390(10106):1949-61; [6] Ledermann JA et al. *Lancet Oncol* 2020;21(5):710-22.

Lancet Oncol 2022;23(4):465-78.

Articles

Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious *BRCA1* or *BRCA2* mutation (ARIEL4): an international, open-label, randomised, phase 3 trial

Rebecca Kristeleit, Alla Lisyanskaya, Alexander Fedenko, Mikhail Dvorkin, Andreia Cristina de Melo, Yaroslav Shparyk, Irina Rakhmatullina, Igor Bondarenko, Nicoletta Colombo, Valentyn Svintsitskiy, Luciano Biela, Marina Nechaeva, Domenica Lorusso, Giovanni Scambia, David Cibula, Róbert Póka, Ana Oaknin, Tamar Safra, Beata Mackowiak-Matejczyk, Ling Ma, Daleen Thomas, Kevin K Lin, Karen McLachlan, Sandra Goble, Amit M Oza

ARIEL4: Progression-Free Survival in the Efficacy and ITT Populations

Efficacy population (BRCA1 or BRCA2 mutations with reversion mutations)



Intent to treat population



Kristeleit et al. *Lancet Oncol* 2022;23(4):465-78.

RTP RESEARCH TO PRACTICE

ARIEL4: Overall Response Rate and Duration of Response

Endpoint	Efficacy population			ITT population		
	Rucaparib (n = 220)	Chemotherapy (n = 105)	*p*-value	Rucaparib (n = 233)	Chemotherapy (n = 116)	*p*-value
ORR	40%	32%	0.13	38%	30%	0.13
DoR, median	9.4 mo	7.2 mo	—	9.4 mo	7.2 mo	—

ORR = overall response rate; DoR = duration of response

Kristeleit et al. *Lancet Oncol* 2022;23(4):465-78.

2021 ESMO congress

Abstract LBA33

Maintenance olaparib rechallenge in patients with ovarian carcinoma previously treated with a PARP inhibitor: Phase IIIb OReO/ENGOT Ov-38 trial

Eric Pujade-Lauraine,[1] Frédéric Selle,[2] Giovanni Scambia,[3] Bernard Asselain,[4] Frederik Marmé,[5] Kristina Lindemann,[6] Nicoletta Colombo,[7] Radoslaw Madry,[8] Rosalind Glasspool,[9] Coraline Dubot,[10] Ana Oaknin,[11] Claudio Zamagni,[12] Florian Heitz,[13] Laurence Gladieff,[14] Maria Jesús Rubio-Pérez,[15] Paolo Scollo,[16] Christopher Blakeley,[17] Bob Shaw,[17] Isabelle Ray-Coquard,[18] Andrés Redondo[19]

OReO Phase IIIB Study Schema



Pujade-Lauraine E et al. ESMO 2021;Abstract LBA33.

OReO: Progression-Free Survival in the BRCAm Cohort



BRCAm cohort	Olaparib (N=74)	Placebo (N=38)
Median follow-up for PFS, months	4.1	2.8
Events, n (%)	65 (88)	38 (100)
Median PFS, months	**4.3**	**2.8**

HR 0.57 (95% CI 0.37–0.87); *P*=0.022

Pujade-Lauraine E et al. ESMO 2021;Abstract LBA33.

OReO: Progression-Free Survival in the Non-BRCAm Cohort



Non-BRCAm cohort	Olaparib (N=72)	Placebo (N=36)
Median follow-up for PFS, months	2.9	2.8
Events, n (%)	48 (67)	30 (83)
Median PFS, months	**5.3**	**2.8**

HR 0.43 (95% CI 0.26–0.71); *P*=0.0023

Pujade-Lauraine E et al. ESMO 2021;Abstract LBA33.

OReO: Progression-Free Survival in the Non-BRCAm Cohort by Homologous Recombination Deficiency (HRD) Status



Pujade-Lauraine E et al. ESMO 2021;Abstract LBA33.

OReO/ENGOT Ov-38 Trial: Impact of Maintenance Olaparib Rechallenge According to Ovarian Cancer Patient Prognosis — An Exploratory Joint Analysis of the BRCA and Non-BRCA Cohorts

Selle F et al.

ASCO 2022;Abstract 5558.

OReO: Post-hoc Analysis of Progression-Free Survival According to Patient Characteristics and Prognostic Factors

Subgroup	Events/N olaparib	Events/N placebo	Hazard ratio (95% CI)	Interaction
Age				0.89
<65	66/84	40/43	0.53 (0.35–0.80)	
≥65	47/62	28/31	0.54 (0.33–0.87)	
Genomic BRCAm and HRD status				0.93
BRCAwt HRD negative	18/31	8/11	0.49 (0.20–1.19)	
BRCAm	65/74	38/38	0.58 (0.38–0.88)	
BRCAwt HRD positive	21/28	13/16	0.53 (0.26–1.09)	
BRCAwt HRD unknown	9/13	9/9	0.44 (0.17–1.18)	
CA-125				0.19
<35	79/104	43/48	0.45 (0.30–0.67)	
≥35	31/39	24/25	0.86 (0.50–1.48)	
ECOG performance status				0.59
0	84/108	44/47	0.57 (0.39–0.83)	
1	29/38	24/27	0.50 (0.28–0.88)	
Visceral site of metastatic disease				0.07
N	71/99	55/60	0.41 (0.29–0.60)	
Y	42/47	13/14	0.87 (0.46–1.64)	
All patients	113/146	68/74	0.54 (0.39–0.73)	



- Olaparib rechallenge was effective regardless of prognostic subgroup
- CA-125 levels and the presence of visceral disease at baseline were the best predictors of patient outcome

Selle F et al. ASCO 2022;Abstract 5558.

RTP RESEARCH TO PRACTICE

Research

JAMA Oncol 2019;5(8):1141-9.

JAMA Oncology | Original Investigation

Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma

Panagiotis A. Konstantinopoulos, MD, PhD; Steven Waggoner, MD; Gregory A. Vidal, MD; Monica Mita, MD; John W. Moroney, MD; Robert Holloway, MD; Linda Van Le, MD; Jasgit C. Sachdev, MD; Eloise Chapman-Davis, MD; Gerardo Colon-Otero, MD; Richard T. Penson, MD; Ursula A. Matulonis, MD; Young Bae Kim, MD; Kathleen N. Moore, MD; Elizabeth M. Swisher, MD; Anniina Färkkilä, MD; Alan D'Andrea, MD; Erica Stringer-Reasor, MD; Jing Wang, PhD; Nathan Buerstatte, MPH; Sujata Arora, MS; Julie R. Graham, PhD; Dmitri Bobilev, MD; Bruce J. Dezube, MD; Pamela Munster, MD

TOPACIO/KEYNOTE-162: Antitumor Activity of Niraparib in Combination with Pembrolizumab



ORR = overall response rate; DCR = disease control rate

Konstantinopoulos PA et al. *JAMA Oncol* 2019;5(8):1141-9.

RTP RESEARCH TO PRACTICE

VIRTUAL 2020 ESMO congress

Abstract 814MO.

Phase II study of olaparib plus durvalumab and bevacizumab (MEDIOLA): initial results in patients with non-germline BRCA-mutated platinum sensitive relapsed ovarian cancer

Yvette Drew,[1] Richard Penson,[2] David M O'Malley,[3] Jae-Weon Kim,[4] Stefan Zimmermann,[5] Patricia Roxburgh,[6] Joohyuk Sohn,[7] Salomon M Stemmer,[8] Sara Bastian,[9] Michelle Ferguson,[10] Benoit You,[11] Susan Domchek,[12] Haiyan Gao,[13] Helen K Angell,[13] Kassondra Meyer,[14] Laura Opincar,[14] Lone Ottesen,[13] Susana Banerjee[15]

[1]Northern Centre for Cancer Care, Newcastle upon Tyne Hospitals NHS Foundation Trust, and Newcastle University, Newcastle upon Tyne, UK; [2]Massachusetts General Hospital, Boston, MA, USA; [3]The Ohio State University – James Comprehensive Cancer Center, Columbus, OH, USA; [4]Seoul National University Hospital, Seoul, Republic of Korea; [5]Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland; [6]Beatson West of Scotland Cancer Centre, and Institute of Cancer Sciences, University of Glasgow, Glasgow, UK, [7]Yonsei Cancer Centre, Yonsei University, Sinchon-dong, Republic of Korea; [8]Rabin Medical Center-Beilinson Campus, Petach Tikva and Tel-Aviv University, Tel-Aviv, Israel; [9]Kantonsspital Graubuenden, Chur, Switzerland; [10]NHS Tayside, Dundee, UK; [11]Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, GINECO, Université Claude Bernard Lyon 1, Lyon, France; [12]Basser Center for BRCA University of Pennsylvania, Philadelphia, PA, USA; [13]AstraZeneca, Cambridge, UK; [14]AstraZeneca, Gaithersburg, MD, USA; [15]The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK

ClinicalTrials.gov identifier: NCT02734004
This study was sponsored by AstraZeneca

RTP RESEARCH TO PRACTICE

MEDIOLA gBRCA Wild Type Study Schema



	Olap + durva + bev (N=31)	Olap + durva (N=32)
Median age, years	64.0	68.5
Age group (years), n (%)		
<50	3 (9.7)	4 (12.5)
≥50–<65	14 (45.2)	8 (25.0)
≥65	14 (45.2)	20 (62.5)
Race, n (%)		
White	20 (64.5)	24 (75.0)
Asian	10 (32.3)	3 (9.4)
Other	1 (3.2)	5 (15.6)
Platinum sensitivity, n (%)		
>6–12 months	18 (58.1)	14 (43.8)
>12 months	13 (41.9)	18 (56.3)
Number of prior lines of chemotherapy, n (%)		
1 prior line	20 (64.5)	23 (71.9)
2 prior lines	11 (35.5)	9 (28.1)
Enrolment completed	January 2019	February 2019
Patients on study treatment at DCO, n (%) (13 February 2020)		
Olap; durva; bev	13 (41.9); 13 (41.9); 12 (38.7)	7 (21.9); 6 (18.8); NA

Drew Y et al. ESMO 2020;Abstract 814MO.

RTP RESEARCH TO PRACTICE

MEDIOLA gBRCA Wild Type: Antitumor Activity



Genomic instability status* subgroup	Olaparib + durvalumab + bevacizumab		Olaparib + durvalumab	
	ORR (95% CI), %	n/N patients	ORR (95% CI), %	n/N patients
GIS-positive	100.0 (69.2–100.0)	10/10	50.0 (18.7–81.3)	5/10
GIS-negative	75.0 (34.9–96.8)	6/8	16.7 (0.4–64.1)	1/6
GIS-unknown	84.6 (54.6–98.1)	11/13	31.3 (11.0–58.7)	5/16

*GIS, as determined by Foundation Medicine tumour analysis; must have genome-wide LOH ≥14, a somatic *BRCA1* and/or *BRCA2* mutation, or a mutation in *ATM*, *BRIP1*, *PALB2*, *RAD51C*, *BARD1*, *CDK12*, *CHEK1*, *CHEK2*, *FANCL*, *PPP2R2A*, *RAD51B*, *RAD51D* or *RAD54L* to be considered positive. At the time of the DCO, the prespecified cut-off for genome-wide LOH of 14% was used[1]; GIS, genomic instability status; IQR, interquartile range; LOH, loss of heterozygosity. [1]Swisher *et al. Lancet Oncol* 2017;18:75–87

Drew Y et al. ESMO 2020;Abstract 814MO.

RTP RESEARCH TO PRACTICE

BARCELONA 2019 ESMO congress

Poster board number: 1190PD

Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in the germline BRCA-mutated platinum-sensitive relapsed ovarian cancer cohort

Yvette Drew,[1] Bella Kaufman,[2] Susana Banerjee,[3] Alain Lortholary,[4] Sook Hee Hong,[5] Yeon Hee Park,[6] Stefan Zimmermann,[7] Patricia Roxburgh,[8] Michelle Ferguson,[9] Ricardo H Alvarez,[10] Susan Domchek,[11] Christopher Gresty,[12] Helen K Angell,[12] Vidalba Rocher Ros,[13] Kassondra Meyer,[13] Mark Lanasa,[13] Pia Herbolsheimer,[13] Maja de Jonge[14]

[1]Northern Centre for Cancer Care, Newcastle upon Tyne Hospitals NHS Foundation Trust Newcastle upon Tyne, UK; [2]Chaim Sheba Medical Center, Tel Hashomer, Israel; [3]The Royal Marsden Hospital, London, UK; [4]Centre Catherine de Sienne, Nantes, France; [5]Seoul St Mary's Hospital, Catholic University of Korea, Seoul, South Korea; [6]Samsung Medical Center, Seoul, Republic of Korea; [7]Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland; [8]University of Glasgow and Beatson West of Scotland Cancer Centre, Glasgow, UK; [9]NHS Tayside, Dundee, UK; [10]Cancer Treatment Centers of America-Atlanta and Augusta University, Augusta, GA, USA; [11]Basser Center for BRCA University of Pennsylvania, Philadelphia, PA, USA; [12]AstraZeneca, Cambridge, UK; [13]AstraZeneca, Gaithersburg, MD, USA and [14]Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, Netherlands

esmo.org

MEDIOLA mBRCA Cohort Study Schema

- MEDIOLA is a multi-cohort, Phase I/II study
- The design of the BRCAm ovarian cohort is presented below; other ovarian cancer cohorts are ongoing

N=34*

- Platinum-sensitive relapsed ovarian cancer†
- Germline mutation in *BRCA1* or *BRCA2*
- ≥1 previous platinum-based therapy
- PARP inhibitor and immunotherapy naïve

Olaparib monotherapy 300 mg bid PO for 4 weeks

then

Olaparib 300 mg bid PO plus **durvalumab** IV 1.5 g every 4 weeks

Treatment until disease progression or intolerable toxicity

Primary endpoints

- Disease control rate at 12 weeks
- Safety and tolerability

Secondary endpoints

- Disease control rate at 28 weeks
- Objective response rate
- Duration of response
- Progression-free survival
- Overall survival
- PD-L1 expression in tumour samples

Drew Y et al. ESMO 2019;Abstract 1190PD.

MEDIOLA mBRCA Cohort: Efficacy

- DCR at 12 weeks: 81.3% (90% CI 66.3, 91.5)
- DCR at 28 weeks: 65.6% (90% CI 49.6, 79.4)
- Unconfirmed ORR: 71.9% (95% CI 53.3, 86.3)
- mPFS: 11.1 months (95% CI 8.2, 15.6)

Greater clinical activity was seen in earlier- versus later-line patients

Time to progression or treatment discontinuation



Best percentage change in target lesion size†



Drew Y et al. ESMO 2019;Abstract 1190PD.

RTP RESEARCH TO PRACTICE

MOONSTONE/GOG-3032: Interim Analysis of a Phase 2 Study of Niraparib + Dostarlimab in Patients (pts) with Platinum-Resistant Ovarian Cancer (PROC)

Randall LM et al.

ASCO 2022;Abstract 5573.

MOONSTONE: Efficacy Summary of Niraparib with Dostarlimab for Platinum-Resistant Ovarian Cancer



Efficacy, n (%) [95% CI]*	Overall N=41	PD-L1 status	
		vCPS ≥5% n=13	vCPS <5% n=25
ORR (CR + PR)	3 (7.3) [1.5–19.9]	1 (7.7) [0.2–36.0]	2 (8.0) [1.0–26.0]
DCR (CR + PR + SD)	12 (29.3) [16.1–45.5]	5 (38.5) [13.9–68.4]	7 (28.0) [12.1–49.4]
Median PFS, months (95% CI)	2.1 (2.0–2.2)	2.2 (1.6–not evaluable)	2.1 (1.8–2.2)

Randall LM et al. ASCO 2022;Abstract 5573.

MOONSTONE: Select Treatment-Related Adverse Events in >10% of Patients

Adverse event n (%)	Related to either niraparib or dostarlimab	Related to niraparib	Related to dostarlimab
Nausea	23 (56.1)	21 (51.2)	11 (26.8)
Fatigue	14 (34.1)	13 (31.7)	13 (31.7)
Vomiting	13 (31.7)	13 (31.7)	7 (17.1)
Anemia	13 (31.7)	13 (31.7)	7 (17.1)
Platelet count decreased	11 (26.8)	11 (26.8)	0 (0)
Thrombocytopenia	8 (19.5)	8 (19.5)	0 (0)

Randall LM et al. ASCO 2022;Abstract 5573.

An Open-Label Phase 2 Study of Dostarlimab, Bevacizumab, and Niraparib Combination in Patients with Platinum-Resistant Ovarian Cancer: Cohort A of the OPAL Trial

Joyce F. Liu,[1] Stéphanie Gaillard,[2] Andrea E. Wahner Hendrickson,[3] John W. Moroney,[4] Oladapo Yeku,[5] Elisabeth Diver,[6] Camille Gunderson,[7] Rebecca Arend,[8] Elena Ratner,[9] Vivek Samnotra,[10] Divya Gupta,[10] Lena Evilevitch,[10] Zebin Wang,[10] Ping Wang,[10] Joseph Tang,[10] Emeline Bacqué,[10] Xiaohong Liu,[10] Gottfried E. Konecny[11]

Poster #23

[1]Dana-Farber Cancer Institute, Boston, MA, USA; [2]Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA; [3]Mayo Clinic Rochester, Rochester, NY, USA; [4]University of Chicago Medicine Comprehensive Cancer Center, Chicago, IL, USA; [5]Massachusetts General Cancer Center, Boston, MA, USA; [6]Stanford Women's Cancer Center, Palo Alto, CA, USA; [7]University of Oklahoma Stephenson Cancer Center, Oklahoma City, OK, USA; [8]The University of Alabama at Birmingham, UAB Comprehensive Cancer Center, Birmingham, AL, USA; [9]Yale University, New Haven, CT, USA; [10]GlaxoSmithKline, Waltham, MA, USA; [11]Ronald Reagan UCLA Medical Center, Los Angeles, CA, USA.

SGO 2021 VIRTUAL ANNUAL MEETING ON WOMEN'S CANCER®

Abstract 10415

SGO Society of Gynecologic Oncology

Antitumor Activity

- Antitumor activity was assessed in the response-evaluable population (n=39)
  - 2 patients in the safety population did not have a postbaseline scan and were excluded from the response-evaluable population
- Response data required that patients with a best response of complete response or partial response had a confirmation scan ≥4 weeks after the first scan in which a response was observed

Antitumor Activity per RECIST v1.1	
Variable, n (%)	**Response-evaluable population (n=39)**
Complete response	0
Partial response	7 (17.9)
Stable disease	23 (59.0)
Progressive disease	8 (20.5)
Inconclusive	1 (2.6)
ORR (90% CI), %	17.9 (8.7–31.1)
DCR (90% CI), %	76.9 (63.2–87.4)

Best Percent Change from Baseline Sum of Target Lesions by HRR and PD-L1 Status



*BRCA*m, *BRCA* mutation; *BRCA*wt, *BRCA* wild type; HRRm, homologous recombination repair mutation; HRRwt, homologous recombination repair wild type; PD-L1, programmed death ligand 1.

SGO 2021 VIRTUAL ANNUAL MEETING ON WOMEN'S CANCER®

Society of Gynecologic Oncology

Liu JF et al. SGO 2021;Abstract 10415.

RTP RESEARCH TO PRACTICE

Novel Investigational Agents and Strategies

Mirvetuximab Soravtansine: Mechanism of Action



(1) Mirvetuximab soravtansine binds with high affinity to FRα expressed on the tumor cell surface

(2) The antibody-drug conjugate (ADC)/receptor complex becomes internalized via antigen-mediated endocytosis

(3) Lysosomal processing releases active DM4 catabolites from the ADC molecule

(4) These maytansinoid derivatives inhibit tubulin polymerization and microtubule assembly

(5) The potent antimitotic effects result in cell-cycle arrest and apoptosis

(6) Active metabolites can also diffuse into neighboring cells and induce further cell death — in other words, bystander killing

Moore K et al. *Future Oncol* 2018:14(2);123-36.

RTP RESEARCH TO PRACTICE

Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study

Ursula A. Matulonis,[1] Domenica Lorusso,[2] Ana Oaknin,[3] Sandro Pignata,[4] Hannelore Denys,[5] Nicoletta Colombo,[6] Toon Van Gorp,[7] Jason A. Konner,[8] Margarita Romeo Marin,[9] Philipp Harter,[10] Conleth G. Murphy,[11] Jiuzhou Wang,[12] Elizabeth Noble,[12] Brooke Esteves,[12] Michael Method,[12] Robert L. Coleman[13]

[1]Dana-Farber Cancer Institute, Boston, MA, USA; [2]Fondazione Policlinico Universitario A. Gemelli, IRCCS and Catholic University of Sacred Heart, Rome, Italy; [3]Gynaecologic Cancer Programme, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain; [4]Istituto Nazionale Tumori di Napoli Fondazione G Pascale IRCCS, Naples, Italy; [5]Ghent University Hospital, Ghent, Belgium; [6]European Institute of Oncology IRCCS, Milan, Italy and University of Milan-Bicocca, Milan, Italy; [7]University Hospital Leuven, Leuven Cancer Institute, Leuven, Belgium; [8]Memorial Sloan Kettering Cancer Center, New York, NY, USA; [9]Institut Català d'Oncologia, Badalona, Spain; [10]Ev. Kliniken Essen-Mitte, Essen, Germany; [11]Bon Secours Hospital and Cancer Trials, Cork, Ireland; [12]ImmunoGen, Inc., Waltham, MA, USA; [13]US Oncology Research, Texas Oncology, The Woodlands, TX, USA



SORAYA

ANNUAL MEETING ON WOMENS' CANCER®
BUILDING BRIDGES // BREAKING BARRIERS
SGO // PHOENIX, ARIZONA // MARCH 18 - 21, 2022

SGO 2022;Abstract LBA4.

Society of Gynecologic Oncology

SORAYA: Investigator-Assessed Objective Response Rate by Prior Therapy



Matulonis UA et al. SGO 2022;Abstract LBA4.

RTP RESEARCH TO PRACTICE

SORAYA: Treatment-Related Adverse Events (≥10%)

TRAEs, n (%)	All Grades	Grade 3	Grade 4
Patients with any event	91 (86)	29 (27)	1 (1)
Blurred vision	43 (41)	6 (6)	0 (0)
Keratopathy*†	38 (36)	8 (8)	1 (1)
Nausea	31 (29)	0 (0)	0 (0)
Dry eye	24 (23)	2 (2)	0 (0)
Fatigue	24 (23)	1 (1)	0 (0)
Diarrhea	23 (22)	2 (2)	0 (0)
Asthenia	16 (15)	1 (1)	0 (0)
Photophobia	15 (14)	0 (0)	0 (0)
Peripheral neuropathy	13 (12)	0 (0)	0 (0)
Decreased appetite	13 (12)	1 (1)	0 (0)
Vomiting	12 (11)	0 (0)	0 (0)
Neutropenia	11 (10)	1 (1)	0 (0)

- Most adverse events (AEs) were low-grade, reversible ocular and GI events
- Serious Grade ≥3 treatment-related AEs (TRAEs) were reported in 8% of patients
- TRAEs led to dose delay in 32% and dose reduction in 19%
- 7 patients (7%) discontinued treatment due to TRAEs
- 1 death was recorded as possibly related to study drug
  - Respiratory failure
  - Autopsy: No evidence of drug reaction; lung metastases

Matulonis UA et al. SGO 2022;Abstract LBA4.

Unique Events Associated with Mirvetuximab Soravtansine: Keratopathy and Blurred Vision

Events developed in 50/106 (47%) patients: mostly low grade



Proactive supportive care
– Lubricating artificial tears
– Corticosteroid eye drops

Predictable
– Median time to onset: cycle 2 (~1.5 months)

Manageable with dose modifications, if needed
– 22% of patients (23/106) had dose delay and/or reduction

Reversible
– At data cutoff: >80% of Grade 2-3 events had resolved to Grade 0-1
  – 9 patients still receiving mirvetuximab soravtansine or being followed up for resolution

<1% discontinuation due to ocular events
– 1 of 106 patients discontinued due to Grade 4 keratopathy, which resolved within 15 days

Matulonis UA et al. SGO 2022;Abstract LBA4.

Mirvetuximab Soravtansine (MIRV) in Patients with Platinum-Resistant Ovarian Cancer with High Folate Receptor Alpha (FRα) Expression: Characterization of Antitumor Activity in the SORAYA Study

Matulonis UA et al.

ASCO 2022;Abstract 5512.

SORAYA: Overall Response Rate in the BRCA Mutation-Positive Subgroup





Matulonis UA et al. ASCO 2022;Abstract 5512.

RTP RESEARCH TO PRACTICE

SORAYA: Overall Response Rate in the BRCA Mutation-Positive Subgroups

	BRCAmt with prior PARPi (n=16)	*BRCAmt* without prior PARPi (n=4)
Responders, n	6	3
ORR	38%	75%

Matulonis UA et al. ASCO 2022;Abstract 5512.

MIRASOL Phase III Study Schema

MIRASOL

Enrollment and Key Eligibility

- Platinum-resistant disease (PFI ≤ 6 mo)
  - 1° platinum refractory disease excluded (primary PFI < 3 mo)
- Prior bevacizumab and PARPi allowed
- 1-3 prior lines of therapy
- Patients with BRCA mutations allowed
- FRα-high by PS2+ scoring (≥75% PS2+)

Statistical Assumptions

- 430 patients/ 330 events for PFS by INV
- α=0.05 (two-sided)
- Power=90%; HR=0.7; control arm mPFS 3.5 mo

Mirvetuximab Soravtansine
6 mg/kg AIBW (calculated using adjusted ideal body weight) intravenously once every 3 weeks

1:1 Randomization
STRATIFICATION FACTORS
Investigator's Choice (IC) Chemotherapy
(Paclitaxel, PLD, Topotecan)
Prior Therapies
(1 vs 2 vs 3)

Investigator's Choice (IC) Chemotherapy
Paclitaxel, PLD,† or Topotecan
Paclitaxel: 80 mg/m2 weekly; PLD: 40 mg/m² every 4 weeks;
Topotecan: 4 mg/m² on days 1, 8, and 15 every four weeks;
or 1.25 mg/m² on days 1-5 every 3 weeks

Moore KN et al. SGO 2022;Abstract 297.

PICCOLO Phase II Trial Schema

PICCOLO

Enrollment and Key Eligibility

- Platinum-sensitive disease (PFI >6 mo)
- At least 2 prior lines of platinum-based therapy
  - Patients with documented platinum allergy require only 1 prior line of platinum
- FRα-high by IHC scoring (≥75% PS2+)
- Appropriate for single agent therapy as next line of therapy as determined by investigator

Statistical Assumptions

- N=75
- Null hypothesis: ORR is ≤ 28% tested using an optimal Simon's two-stage design w/o pause in enrollment

→

Mirvetuximab Soravtansine

6 mg/kg AIBW (calculated using adjusted ideal body weight) intravenously once every 3 weeks

Alvarez Secord A et al. SGO 2022;Abstract 300.

2021 ASCO ANNUAL MEETING

Abstract 5504

Mirvetuximab Soravtansine, a folate receptor alpha-targeting antibody drug conjugate, in combination with bevacizumab in patients with platinum-agnostic ovarian cancer: final analysis

David M. O'Malley[1], Ana Oaknin[2], Ursula A. Matulonis[3], Gina M. Mantia-Smaldone[4], Peter Lim[5], Cesar Castro[6], Diane Provencher[7], Sanaz Memarzadeh[8], Patrick Zweidler-McKay[9], Jiuzhou Wang[9], Brooke Esteves[9], Kathleen N. Moore[10] Lucy Gilbert[11]

[1]Ohio State University, Columbus, OH; [2]Vall D´Hebron University Hospital, Vall D'Hebron Institute of Oncology (VHIO), Barcelona, Spain; [3]Dana Farber Cancer Institute, Boston, MA; [4]Fox Chase Cancer Center, Philadelphia, PA; [5]The Center of Hope Renown Regional Medical Center, Reno, NV; [6]Massachusetts General Hospital, Boston, MA; [7]Institute du Cancer de Montreal, Montreal, Canada; [8]Ronald Reagan UCLA Medical Center UCLA Medical Center, Santa Monica; [9]ImmunoGen, Inc., Waltham, MA; [10]University of Oklahoma Health Sciences Center, Oklahoma City, OK/Sarah Cannon Research Institute, Nashville, TN; [11]McGill University Health Center-RI, Montreal, Canada



RTP RESEARCH TO PRACTICE

Confirmed ORR by FRα Expression and Platinum Status



- **50% ORR** (30/60) for overall cohort
- **64% ORR** (21/33) in high FRα tumors
  - **59% ORR** (10/17) in PROC subset
  - **69% ORR** (11/16) in PSOC subset

ORR = overall response rate; PROC = platinum-resistant ovarian cancer; PSOC = platinum-sensitive ovarian cancer

O'Malley DM et al. ASCO 2021;Abstract 5504.

Median Duration of Response (mDOR) by FRα Expression and Platinum Status



- **9.7 mo mDOR** for overall cohort
- **11.8 mo mDOR** in high FRα tumors
  - **9.4 mo mDOR** in PROC subset
  - **12.7 mo mDOR** in PSOC subset

*Upper limit of 95% confidence interval not reached

O'Malley DM et al. ASCO 2021;Abstract 5504.

RTP RESEARCH TO PRACTICE

High FRα Tumors Showed a Deep Response and Durable Benefit

Maximum % Change from Baseline



- **97% (32/33)** of patients demonstrated tumor burden reduction

Percent Change and Duration from Baseline



- Rapid tumor shrinkage, with early responses
- Durable benefit in both PSOC and PROC

O'Malley DM et al. ASCO 2021;Abstract 5504.

Updated Results From the Phase 1b Expansion Study of Upifitamab Rilsodotin (UpRi; XMT-1536), a NaPi2b-directed Dolaflexin Antibody Drug Conjugate (ADC) in Ovarian Cancer

Richardson, Debra L[1]; Hamilton, Erika P[2]; Barve, Minal[3]; Anderson, Charles K[4]; Taylor, Sara K[5]; Lakhani, Nehal[6]; Buscema, Joseph[7]; Tolcher, Anthony W[8]; Zarwan, Corrine[9]; Werner, Theresa L[10]; Hays, John L[11]; Richards, Paul[12]; Arend, Rebecca[13]; Edenfield, Jeffery[14]; Putiri, Emily[15]; Bernardo, Patricia[15]; Burger, Robert A[15]; Matulonis, Ursula A[16]

[1]Stephenson Cancer Center, University of Oklahoma Health Sciences Center and the Sarah Cannon Research Institute, Oklahoma City, OK; [2]Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; [3]Mary Crowley Cancer Research, Dallas, TX; [4]Willamette Valley Cancer Institute and Research Center, Eugene, OR; [5]BC Cancer - Kelowna, Kelowna BC, Canada; [6]START Midwest, Grand Rapids, MI; [7]Arizona Oncology, Tucson, AZ; [8]NEXT Oncology, San Antonio, TX; [9]Lahey Clinic, Burlington, MA; [10]Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; [11]Arthur James Cancer Hospital, Ohio State University, Columbus, OH; [12]US Oncology, Oncology and Hematology Assoc. of Southwest VA, Salem, VA; [13]University of Alabama at Birmingham, Birmingham, AL; [14]Prisma Health Cancer Institute, Greenville, SC; [15]Mersana Therapeutics, Inc, Cambridge, MA; [16]Dana-Farber Cancer Institute, Boston, MA

Abstract 76

ANNUAL MEETING ON WOMENS' CANCER®
BUILDING BRIDGES // BREAKING BARRIERS
SGO // PHOENIX, ARIZONA // MARCH 18 - 21, 2022

SGO 2022;Abstract 76.

Society of Gynecologic Oncology

Upifitamab Rilsodotin (UpRi): First-in-Class ADC Targeting NaPi2b



UpRi

Antibody: Humanized monoclonal anti-NaPi2b[1]

Linker: Polymer scaffold; cleavable ester linker[2]

Payload: AF-HPA (DolaLock-controlled bystander effect)[1]

Drug-to-Antibody Ratio: ~10



Upon ADC internalization into tumor cells and efficient release of payload, AF-HPA payload is metabolized to AF that remains highly potent but loses the ability to cross the cell membrane, locking it in the tumor, controlling the bystander effect, and consequently limiting impact on adjacent healthy cells[2,3]

NaPi2b Is a Sodium-Dependent Phosphate Transporter Broadly Expressed in Ovarian Cancer With Limited Expression in Healthy Tissues[4]

- NaPi2b expressed by tumor cells in two-thirds of patients with high-grade serous ovarian cancer[2]
- NaPi2b is a lineage antigen (not an oncogene)[1]



NaPi2b IHC assay in development *– an optimal diagnostic assay would be robust, predictive, reproducible, easily able to distinguish a wide range of expression using* ***TPS scoring method***[2]



Richardson DL et al. SGO 2022;Abstract 76.

RTP RESEARCH TO PRACTICE

UpRi Phase Ib Study Schema

Patient Population: HGSOC[a] progressing after standard treatments; measurable disease per RECIST v1.1; ECOG PS 0 or 1

Ovarian Cancer Cohort
- 1–3 prior lines in platinum-resistant
- 4 prior lines regardless of platinum status
- High-grade serous histology
- Archived tumor and fresh biopsy (if medically feasible) for NaPi2b
- Exclusion: Primary platinum-refractory disease

UpRi IV Q4W until disease progression or unacceptable toxicity

36 mg/m² cohort initiated in August 2019

43 mg/m² to a max of ~80 mg cohort initiated in December 2019

Primary Objectives
- Evaluate safety and tolerability of MTD or RP2D
- Assess preliminary efficacy (ORR, DCR)

Secondary Objectives
- Association of tumor NaPi2b expression and objective tumor response using an IHC assay with a broad dynamic range to distinguish tumors with high and low NaPi2b expression
- Further assessment of preliminary anti-neoplastic activity (DoR)

Assessment: Tumor imaging (MRI or CT) at baseline and every 2nd cycle; response assessed per RECIST v1.1

Richardson DL et al. SGO 2022;Abstract 76.

Expansion Cohort Experience Across a Range of Doses Allowed for Further Optimization of UpRi Profile

Updated Analysis of Phase 1b PROC Expansion Cohort to Evaluate Safety and ORR Based on UpRi Dose Levels[a]

Dose Group 36 (33–38 mg/m²) (n=29)

12 patients at **36 mg/m²** starting dose (all BSA levels)

+

17 patients at ~80 mg starting dose with BSA ≥1.8 who received an actual dose of **33 to 38 mg/m²**

Dose Group 43 (>38–43 mg/m²) (n=66)

39 patients at **43 mg/m²** starting dose with BSA <1.8

+

27 patients at ~80 mg starting dose with BSA ≥1.8 who received an actual dose of **>38 mg/m²**

Richardson DL et al. SGO 2022;Abstract 76.

TRAEs by UpRi Dose Group

Dose Group 36 Had a More Favorable Safety Profile Compared to Dose Group 43



- No severe ocular toxicity, neutropenia, or peripheral neuropathy in either dose group
- 4 (14%) patients had treatment-related SAEs in Dose Group 36 vs 18 (27%) in Dose Group 43
- Lower frequencies and lower grade pneumonitis occurred in Dose Group 36 (with no Grade 3+) vs Dose Group 43[a]

Richardson DL et al. SGO 2022;Abstract 76.

RTP RESEARCH TO PRACTICE

Best Response by UpRi Dose Group

Similar Tumor Reduction in Both Dose Groups: Two-thirds of Patients Had Reductions in Target Tumor Lesions by RECIST 1.1



Richardson DL et al. SGO 2022;Abstract 76.

Confirmed ORR by UpRiDose Group and NaPi2b Level and Duration of Response (DoR)

		All Dose Levels	Dose Group 36	Dose Group 43
NaPi2b-High (TPS ≥75)	N	38	16	22
	ORR, n (%)	**13 (34)**	**7 (44)**	**6 (27)**
	CR, n (%)	2 (5)	2 (13)	0
	PR, n (%)	11 (29)	5 (31)	6 (27)
	DCR, n (%)	33 (87)	12 (75)	21 (95)
All NaPi2b Levels	N	75	25	48
	ORR, n (%)	**17 (23)**	**9 (36)**	**8 (17)**
	CR, n (%)	2 (3)	2 (8)	0
	PR, n (%)	15 (20)	7 (28)	8 (17)
	DCR, n (%)	54 (72)	18 (72)	35 (73)

- **Median DoR in patients (all dose levels) with NaPi2b-high ovarian cancer (n=13): 5 months**
- No obvious difference in median DoR observed between Dose Groups 36 and 43

Richardson DL et al. SGO 2022;Abstract 76.

Time on UpRi Study in Evaluable Patients



Richardson DL et al. SGO 2022;Abstract 76.

Ongoing UPLIFT (ENGOT-OV67/GOG-3048) Study Schema



Richardson DL et al. SGO 2022;Abstract 76.

Ongoing UP-NEXT Phase III (ENGOT-OV71-NSGO-CTU/GOG-3049) Study Schema



Richardson DL et al. SGO 2022;Abstract 76.

Relacorilant + Nab-paclitaxel Phase 2 Study Design

Randomized 1:1:1

- Measurable or non-measurable disease by RECIST v1.1
- Up to 4 prior chemotherapeutic regimens

Stratification factors:

- Relapse within 6 months of most recent taxane
- Presence of ascites



Primary endpoint:

- Progression-free survival (PFS) by investigator and RECIST v1.1

Secondary endpoints:

- Objective response rate (ORR)
- Duration of response (DoR)
- Overall survival (OS)
- Safety of the relacorilant + nab-paclitaxel combination

Statistical assumptions:

- **CONTINUOUS vs COMPARATOR**: 91 PFS events to detect a HR=0.56 (median PFS increase from 3.8 to 6.8 mo)
- **INTERMITTENT vs COMPARATOR**: 92 PFS events to detect a HR=0.7 (median PFS increase from 3.8 to 5.4 mo)

PFS analysis reported at ESMO 2021

Colombo N et al. ASCO 2022;Abstract LBA5503; Liu N. ASCO 2022;Highlights of the Day: Gynecologic Cancers.

Investigator assessed PFS and OS of relacorilant + nab-paclitaxel

Progression free survival



	INTERMITTENT* N=60	CONTINUOUS N=58	COMPARATOR N=60
Events, no. (%)	47 (78.3%)	50 (86.2%)	57 (95.0%)
Median PFS, mo (95% CI)	5.6 (3.7, 7.2)	5.3 (3.8, 5.6)	3.8 (3.5, 5.4)
HR vs Comparator	0.66 (0.44, 0.98)	0.83 (0.56, 1.22)	N/A

* *P*-value=0.038 vs. nab-paclitaxel alone; no multiplicity adjustment
Median follow-up time: 11.1 months
Data cutoff: March 22, 2021

Overall survival



	INTERMITTENT* N=60	CONTINUOUS N=58	COMPARATOR N=60
Events, no. (%)	37 (61.7%)	42 (72.4%)	49 (81.7%)
Median OS, mo (95% CI)	13.9 (11.1, 18.4)	11.3 (7.5, 16.4)	12.2 (7.7, 15.3)
HR vs Comparator	0.67 (0.43, 1.03)	0.85 (0.56, 1.29)	N/A

* *P*-value=0.066 vs. nab-paclitaxel alone
Median follow-up time: 22.5 months
Data cutoff: March 7, 2022

Colombo N et al. ASCO 2022;Abstract LBA5503; Liu N. ASCO 2022;Highlights of the Day: Gynecologic Cancers.

Meet The Professor

Current and Future Management of Non-Small Cell Lung Cancer with an EGFR Mutation

Wednesday, August 31, 2022
5:00 PM – 6:00 PM ET

Faculty

Lecia V Sequist, MD, MPH

Moderator

Neil Love, MD

RTP
RESEARCH
TO PRACTICE

Thank you for joining us!

CME and MOC credit information will be emailed to each participant within 5 business days.

RTP
RESEARCH
TO PRACTICE